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ABSTRACT 
An Investigation of Bacterial Ribonucleases as an Antibiotic Target 
by 
Ashley Denise Frazier 
 
Antibiotics have been commonly used in medical practice for over 40 years. However, the 
misuse and overuse of current antibiotics is thought to be the primary cause for the increase in 
antibiotic resistance. 
  
Many current antibiotics target the bacterial ribosome. Antibiotics such as aminoglycosides and 
macrolides specifically target the 30S or 50S subunits to inhibit bacterial growth. During the 
assembly of the bacterial ribosome, ribosomal RNA of the 30S and 50S ribosomal subunits is 
processed by bacterial ribonucleases (RNases). RNases are also involved in the degradation and 
turnover of this RNA during times of stress, such as the presence of an antibiotic. This makes 
ribonucleases a potential target for novel antibiotics. 
 
It was shown that Escherichia coli mutants that were deficient for RNase III, RNase E, RNase R, 
RNase G, or RNase PH had an increase in ribosomal subunit assembly defects. These mutant 
bacterial cells also displayed an increased sensitivity to neomycin and paromomycin antibiotics. 
My research has also shown that an inhibitor of RNases, vanadyl ribonucleoside complex, 
potentiated the effects of an aminoglycoside and a macrolide antibiotic in wild type Escherichia 
coli, methicillin sensitive Staphylococcus aureus, and methicillin resistant Staphylococcus 
aureus. 
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RNases are essential enzymes in both rRNA maturation and degradation. Based on this and 
previous work, the inhibition of specific RNases leads to an increased sensitivity to antibiotics. 
This work demonstrates that the inhibition of RNases might be a new target to combat antibiotic 
resistance. 
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CHAPTER 1 
INTRODUCTION 
 
Antibiotic Overview 
 Antibiotic resistance is a growing concern in the medical and research fields and is thought 
to occur due to excessive use of current antibiotics in treating humans, animals, and agriculture. 
In some cases, hospital-acquired bacterial infections have become almost untreatable due to 
increasing antibiotic resistance. A summary diagram of antibiotic use for humans, animals, and 
in the environment is seen in Figure 1.1 and depicts how the use of antibiotics in one group can 
migrate to affect other groups (Davies and Davies 2010; Giedraitienė and others 2011; Rosen 
2011; Tenover 2001). In addition to drug resistance among the pathogenic bacteria, there is also 
a documented increase in antibiotic resistance of the normal flora. An example of this is 
Escherichia coli, a gram negative bacterial species that is found in the normal flora of the human 
bowels. This bacterial species has become a leading cause of urinary tract infections (Erb and 
others 2007). Previous studies have demonstrated the increase in antibiotic resistance is not due 
solely to hospital-acquired infections. Antibiotic resistant bacteria were originally thought to be 
nosocomial, but these data indicates that community-acquired infections are becoming more 
common, confirming that the spread of resistance is becoming more and more serious. 
 Before the 1940s, common treatments for bacterial infections were to insert a surgical drain 
into the site of the infection and use antiseptics, but this was not an adequate treatment and many 
bacterial infections were still fatal. A few years after antibiotics were first used to treat bacterial 
infections, penicillin resistance began to occur. Since then, resistance has grown to encompass 
various other antibiotics, including methicillin and vancomycin (Zinner 2005; 2007). By the 
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1990s, methicillin resistant Staphylococcus aureus was no longer limited to hospital-acquired 
infections, and community-acquired S. aureus began to appear more often (Hawkey and Jones 
2009; Zinner 2007). Multiple bacteria species are now developing resistance to currently used 
antibiotics, including Staphylococcus aureus, Escherichia coli, Pseudomonas aeruginosa, and 
Mycobacterium tuberculosis (Giedraitienė and others 2011). In order to alleviate this growing 
problem, researchers are attempting to identify new antibiotic targets and to create novel 
antibiotics that contain unique structures to which resistance has not developed (Anderson 1999; 
Cars and others 2011; Högberg and others 2010). Antibiotic resistance is thought to occur by 
multiple different mechanisms. Some of these mechanisms include acquisition of resistance 
genes, up-regulation of genes encoding cellular efflux pumps, and spontaneous mutations 
(Zinner 2007). However, a better understanding of current antibiotic targets and how they 
function in cells will allow for increased efficiency in antibiotic research. 
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Figure 1.1: Overview of antibiotic use (Davies and Davies 2010). This figure indicates the use of 
antibiotic in the ecosystem is not restricted to that group. The use of antibiotics in the 
environment affects animals, humans, and the use of antibiotics in each of these groups also 
affect the environment. (Used with permission) 
 
Antibiotic Targets 
 Bacterial ribosomes are composed of a small 30S and a large 50S subunit (Champney 2006). 
The 30S ribosomal subunit is composed of 16S ribosomal RNA (rRNA) and 21 proteins, while 
the 50S ribosomal subunit is composed of 23S and 5S rRNA and 34 proteins. Both the large and 
small subunits must be present to create the bacterial ribosome. Each subunit contains a specific 
center essential to translation. The 30S subunit contains a decoding center, and the 50S subunit 
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contains a peptidyl-transferase center. The decoding center is essential to the A binding site, and 
the PTC center is essential to the P binding site (Wilson 2009). Research has shown that 
antibiotics targeting these essential centers of the 30S and 50S subunits inhibit both subunit 
assembly and bacterial protein synthesis (Champney 2006; McCoy and others 2011; Siibak and 
others 2011). This indicates that inhibition of ribosomal subunit assembly and translational 
inhibition might be a synergistic process (Champney 2006). 
 Many antibiotics act as translational inhibitors (Champney 2006; McCoy and others 2011; 
Wilson 2009). During translation, mRNA brings a genetic code to the ribosome, and tRNA 
carries the amino acids to the ribosome. For processing to continue, the mRNA and the tRNA 
must move through the ribosome, i.e. progression must occur from the A site to the P site and 
finally through the E site of the ribosome. The ribosome serves as a platform for the tRNA to 
read the mRNA and create a nascent polypeptide chain. This is known as an elongation cycle 
that must involve the decoding of the mRNA (at the small ribosomal subunit by tRNA), the 
formation of a peptide bond, and release of the tRNA molecule at the peptidyl-transferase center 
(PTC) of the large ribosomal subunit (Kaczanowska and Rydén-Aulin 2007). Decoding of the 
mRNA by tRNA occurs within the A site. Next the tRNA carrying the nascent polypeptide chain 
is moved to the P site for peptide bond formation. Finally, the tRNA that is ready to exit the 
ribosome is moved to the E site. This tRNA is ready to exit the ribosome because it has 
transferred the amino acid to the nascent chain and is now uncharged (Wilson 2009). Once the 
mRNA has been completely read, the recycling of ribosomal subunits of the 70S ribosome is the 
final step in the protein synthesis cycle and must be completed in order to repeat the cycle 
(Borovinskaya and others 2007; Kaczanowska and Rydén-Aulin 2007; McCoy and others 2011; 
Poehlsgaard and Douthwaite 2005; Ramakrishnan 2002; Yonath 2005). A diagram of the 
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mechanism of translation is seen in Figure 1.2 (Ramakrishnan 2002). Many antibiotics act by 
targeting the decoding and PTC centers to inhibit protein synthesis in a bacterial cell (Wilson 
2009). In addition to translation, another target of many antibiotics is the formation of the 
bacterial ribosome (Champney 2001; 2006; Wallis and Schroeder 1997). 
  
 
Figure 1.2: A diagram of translation (Ramakrishnan 2002). The following figure indicates the 
progression of tRNA through the A, P, and E sites of the bacterial ribosome as it reads mRNA. 
(Used with permission) 
 
 When assembly of either of the ribosomal subunits is inhibited, ribonucleases (RNases) have 
been found to degrade the ribosomal subunit assembly intermediates as seen in Figure 1.6 
(Champney 2006). RNases are involved in rRNA processing to generate the 30S and 50S 
ribosomal subunit and RNA degradation. When an inhibitor, such as an antibiotic, is introduced 
specific RNases function in the recycling of the ribosomal precursors via rRNA turnover. This 
makes bacterial ribosome formation and RNases two important targets for the development of 
novel antibiotics to help fight antibiotic resistance. In order to understand antibiotic resistance, it 
is important to first have a basic knowledge of antibiotic functions. 
 Two families of antibiotics that specifically target both translation and ribosomal subunit 
assembly are the aminoglycoside and macrolide antibiotics. Aminoglycosides specifically target 
the bacterial ribosome and not eukaryotic ribosomes due to differences in amino acids at the 
target site on the ribosome and in cell membrane permeability (McCoy and others 2011). 
18 
 
Neomycin and paromomycin  are two aminoglycosides that have been demonstrated to inhibit 
30S ribosomal subunit assembly in wild type E. coli (Foster and Champney 2008; Mehta and 
Champney 2002) and in S. aureus (Mehta and Champney 2003). Aminoglycosides have also 
been shown to bind to the 50S ribosomal subunit (Borovinskaya and others 2007; Campuzano 
and others 1979; Scheunemann and others 2010). The aminoglycoside antibiotics have a positive 
charge that allows for the strong attraction to the negatively charged RNA (Shakil and others 
2008). These antibiotics work by targeting both 30S and 50S ribosomal subunit assembly. 
Treatment with neomycin (Figure 1.3), a member of the aminoglycoside family, has been found 
to degrade the bacterial ribosome subunits by 60% in glucose starved cells (Zundel and others 
2009). One interpretation of the decrease is that ribosomal subunits that are not assembled into 
active ribosomes are subject to degradation by bacterial ribonuclease.  
 
 
Figure 1.3: Structure of neomycin 
Ring I 
Ring II 
Ring III 
Ring IV 
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 Research indicates that the two main binding sites for aminoglycosides are 16S rRNA helix 
44 and 23S rRNA helix 69 (Feldman and others 2010; Scheunemann and others 2010). The 
binding reduces, or in some cases completely inhibits, the ability of the ribosome recycling factor 
to recycle ribosomes by blocking this area of 23S rRNA. Helix 69 is also responsible for forming 
a bridge with the smaller 30S ribosomal subunit and the A and P sites of the ribosome. When the 
A site is blocked, the transfer from the A site to P site malfunctions and mistranslation occurs 
(Borovinskaya and others 2007; Hirokawa and others 2005; Scheunemann and others 2010; 
Schroeder and others 2000; Yonath 2005). 
 When binding to the 30S subunit, aminoglycosides bind to helix 44 of 16S rRNA. This 
binding displaces two adenine residues and leads to a stabilized confirmation of one or more of 
the four inter-subunit bridges.  These two adenine residues are located in the A site of the 
ribosome and when displaced, the mRNA and tRNA binding specificities to this site are 
decreased leading to mistranslation and eventual cell death (Sutcliffe 2005). Paromomycin 
(Figure 1.4) is thought to function by binding to the 16S rRNA. In this antibiotic, ring IV makes 
contact with both sides of the helix 44 while ring I inserts itself into the RNA helix and is 
directly responsible for the displacement of adenine 1492 and adenine 1493 (Carter and others 
2000). This displacement inhibits the movement of the 70S ribosome, thereby inhibiting the 
translocation of transfer RNA to a new position on the ribosome. The increased stabilization also 
prevents dissociation of the 30 and 50S ribosomal subunits and subsequent ribosome recycling 
(Carter and others 2000; Długosz and Trylska 2009; Sutcliffe 2005; Tenson and Mankin 2006). 
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Figure 1.4: Structure of paromomycin  
 
 Macrolide antibiotics are a family of antibiotics that have a 12-16 membered macrolactone 
ring and include the antibiotics erythromycin and azithromycin (Figure 1.5). Macrolides have not 
been shown to affect 30S subunit formation even at high antibiotic concentrations (Silvers and 
Champney 2005). These antibiotics function by binding to the upper portion of the peptide exit 
tunnel, below the peptidyl-transferase center of the 50S ribosome. The binding occurs at 
nucleotides A2058 and A2059 via hydrogen bonds. This binding places the lactone ring of 
macrolides against the exit tunnel and blocks it so that the newly made peptide chain cannot 
elongate. The growth of the peptide chain is hindered depending on the bulk of the macrolide 
antibiotic, so that the bulkier antibiotics will result in a shorter peptide chain  
Ring I 
Ring II 
Ring III 
Ring IV 
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(Bogdanov and others 2010; Kannan and Mankin 2011; Sutcliffe 2005; Tenson and Mankin 
2006). Macrolides, such as azithromycin, are derivatives of the original macrolide, erythromycin, 
and are more flexible due to having a 15 membered macrolactone ring rather than the original 14 
membered ring. The altered ring also has an increased size and leads to the antibiotic occupying 
more space in the exit tunnel. With more space being occupied in the exit tunnel, the antibiotic 
efficiency for inhibiting the elongation of the protein in increased (Yonath 2005). When binding 
to the ribosome, only one molecule of azithromycin can bind to a single ribosome (Petropoulos 
and others 2009). In addition to blocking polypeptide elongation, macrolide antibiotics can also 
bind to an intermediate of the 50S subunit, the 32S precursor. When wild type S. aureus cells or 
RNase E deficient E. coli cells were incubated with erythromycin, there was an accumulation of 
23S rRNA and 32S precursor. These data are indicative of stalling of the assembly of the 50S 
ribosomal subunit (Pokkunuri and Champney 2007; Usary and Champney 2001). It has also been 
determined that macrolide selectivity for bacteria is based on the adenine at position 2058 of 23S 
rRNA. This adenine is conserved in bacteria but in eukaryotes it is a guanine residue (Mankin 
2008; McCoy and others 2011; Starosta and others 2010). 
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Figure 1.5: Structure of azithromycin 
 
 These data, taken together, describe the mechanisms of action for two classes of antibiotics. 
By better understanding the mechanisms of actions of current antibiotics, new targets for novel 
antibiotics can be explored to fight against antibiotic resistance. 
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Figure 1.6: Diagram of bacterial ribosome assembly. This diagram shows that RNases are 
involved in ribosomal precursor processing and rRNA turnover (Champney 2006) 
 
Bacterial Ribonucleases 
 Extensive research has been conducted to determine the functions of various ribonucleases 
in rRNA maturation, rRNA degradation, and ribosomal subunit assembly. In the bacterial cell, 
there are three main categories of RNA: messenger RNA (mRNA), transfer RNA (tRNA), and 
ribosomal RNA (rRNA). Between these categories, rRNA is the most abundant, and mRNA has 
the largest turnover rate (Li and others 2002). RNases play key roles in the degradation and 
maturation of each of these types of RNA. For example, RNase PH has been found to be 
involved in the processing and degradation of tRNA (Kelly and others 1992; Li and Deutscher 
1994). mRNA degradation begins with the endonucleolytic cleavage by RNase E. RNase II then 
functions in degradation of the poly(A) tail and subsequent degradation of mRNA  
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(Mohanty and Kushner 2000). Once bound to the ribosome for translation, a region of 15 
nucleotides in mRNA is protected from degradation by RNases (Rauhut and Klug 1999). These 
are just a few of the functions of RNases involving mRNA and tRNA. RNases also have 
significant roles in maturation and in degradation of the most abundant RNA in a bacterial cell, 
ribosomal RNA. 
 During assembly of the 30S and 50S ribosomal subunits, ribonucleases have been shown to 
play a key role in rRNA turnover when an inhibitor is present (Champney 2006).  It was 
previously concluded by Silvers and Champney that E. coli strains deficient for certain RNases 
were enhanced in their sensitivity to the macrolide, azithromycin (Silvers and Champney 2005).  
Strains deficient in RNase E or polynucleotide phosphorylase (PNPase) were hypersensitive to 
azithromycin. In addition to an increased sensitivity to azithromycin, E. coli with these RNase 
deficiencies showed an accumulation of 23S rRNA and a reduced recovery rate of subunit 
formation after the removal of the antibiotic. It was ascertained that azithromycin decreased the 
assembly of the 50S ribosomal subunit and increased the accumulation of the 32S precursor to 
the 50S ribosomal subunit (Silvers and Champney 2005). Figure 1.6 depicts the pathway for 50S 
synthesis (Champney 2006). After azithromycin removal, the recovery rate of the 50S ribosomal 
subunit was slowest in RNase E deficient, PNPase deficient, or RNase II deficient E. coli strains. 
These data suggest that RNase E, RNase II, and PNPase play an important role in 23S rRNA 
turnover and identify a possible mechanism for antibiotic resistance (Silvers and Champney 
2005). It is possible that an increase in RNases leads to a decrease in antibiotic sensitivity and an 
inhibition of specific RNases will lead to an increase in antibiotic sensitivity. A summary of 
these data can be seen in Table 1.1.  
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Table 1.1: Effect on ribosome deficiency on azithromycin sensitivity and 50S subunit assembly 
in E. coli. Adapted from Silvers and Champney (Silvers and Champney 2005) 
 
  Function Azithromycin Effect 
RNase Type Synthesis Degradation Sensitivity Inhibit 50S Assembly Increased rRNA Fragmentation 
I Endo  +    
II Exo  + + + + 
III Endo + +    
E Endo + + + + + 
PNPase Exo  + + + + 
 
 Silvers and Champney’s work illustrates the importance of RNases in the turnover of 23S 
rRNA in the presence of a macrolide antibiotic (Silvers and Champney 2005). A better 
understanding of the function of some of the currently recognized RNases can provide a more 
focused use for antibiotics. A list of some of the known ribonucleases is shown in Table 1.2. 
Based on the functions of RNases and previous work showing that E. coli deficient for specific 
RNases displayed a reduction in ribosomal subunit formation (Silvers and Champney 2005; 
Usary and Champney 2001), it is possible that RNases could be used as a novel antibiotic target. 
Compounds which subsequently block RNases that function in ribosome assembly or 
degradation would be predicted to affect the sensitivity of current antibiotics. 
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Table 1.2: Summary of ribonuclease functions 
 
  Function 
RNase Type of Ribonuclease Maturation Degradation 
I Endo  Yes 
II Exo Yes Yes 
III Endo Yes Yes 
E Endo Yes Yes 
G Endo Yes  
R Exo  Yes 
PNPase Exo  Yes 
PH Exo Yes Yes 
 
RNase I 
 RNase I is an endoribonuclease located in the periplasmic region of the bacterial cell. It 
functions in cleavage of RNA and is used as a defense mechanism against invasion by 
bacteriophage (Arraiano and others 2010; Raziuddin and others 1979). Degradation of RNA can 
occur by this enzyme due to cell damage. When the cell is damaged, it is hypothesized that 
RNase I is able to leave the periplasmic region, enter into the cell, and degrade ribosomal RNA. 
It is theorized that RNase I functions to forage nucleotides from the extracellular environment 
(Arraiano and others 2010). However, the enzyme is normally kept inactive by unknown 
mechanisms (Deutscher 2006; 2009).  
 
RNase III 
 RNase III is an endoribonuclease encoded by the rnc gene and is responsible for cleavage of 
the primary rRNA transcript (Allas and others 2003; MacRae and Doudna 2007). This cleavage 
separates rRNA precursors into 17S, 25S, and 9S precursors, as seen in Figure 1.7, and initiates 
ribosomal subunit RNA processing (Kaczanowska and Rydén-Aulin 2007). Figure 1.7 is a 
diagram of how various RNases process ribosomal RNA (Davies and others 2010). RNase III is 
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involved in the cleavage of  dsRNA (Xiao and others 2009). 16S and 23S rRNA sequences form 
double-stranded regions at the 3’ and 5’ ends that must be removed in order to further process 
the rRNA into the mature forms. King et al. determined that in an RNase III deficient E. coli 
strain, the 16S rRNA had a mature 5’ end and 3’ end while the 23S rRNA did not have a mature 
5’ or 3’ end (King and others 1984). These results further demonstrated that RNase III was 
mechanistically the first RNase to cleave the primary RNA transcript (King and others 1984). 
Further research has found that in α-proteobacteria, RNase III cleaves 23S rRNA at helix 9 of the 
3’ terminus. This cleavage is important to the maturation of the 3’ terminus (Evguenieva-
Hackenberg and Klug 2000).  
 Final maturation of both 23S and 16S occurs via additional ribonucleases. Without RNase 
III and the initial cleavage, rRNA maturation will not occur. RNase III has been shown to 
interact with the 70S ribosome and the ribosomal subunits (Allas and others 2003). This 
interaction is thought to play a role in rRNA precursor maturation. RNase III cleaves the 23S 
rRNA precursor 3 nucleotides downstream of the mature 5’ terminus in the ribosome. RNase III 
has also been implicated in final maturation of ribosomal RNA, which occurs when RNase III 
binds to the 70S ribosome to facilitate final 23S rRNA maturation within the ribosome (Allas 
and others 2003). 
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Figure 1.7: A diagram indicating significant functions of some RNase in RNA maturation. 
Modified from Davies et al. 2010 (Davies and others 2010). The diagram shows that RNase III is 
responsible for the initial cleavage of the rRNA transcript. In order to produce functional 16S, 
23S, and 5S rRNA, additional RNases are necessary for maturation. (Used with permission) 
 
 
RNase E 
 RNase E is an endoribonuclease, encoded by the rne gene, that forms part of the 
degradosome particle with the enzyme polynucleotide phosphorylase (PNPase), an 
exoribonuclease involved in RNA decay (Arraiano and others 2010).  These two ribonucleases, 
along with enolase and the DEAD-box helicase RhlB interact to form the degradosome (Vanzo 
and others 1998). This complex is responsible for degradation of rRNA in addition to mRNA. 
RNase E is an important enzyme in this complex because the other three components of the 
degradosome each bind to the carboxyl-terminal end of RNase E. This further demonstrates the 
significance of RNase E in RNA degradation. Along with the ribonucleases, RhlB is responsible 
for unwinding the RNA to allow for degradation. Enolase has an undefined function within the 
29 
 
degradosome (Vanzo and others 1998; Worrall and Luisi 2007). Studies have revealed that 
mutations eliminating the C-terminus of RNase E result in a disruption of the degradosome 
particle. However, the loss of the C-terminus also led to a reduction in cell growth, an increase in 
stabilized mRNA, and 5S rRNA maturation remained unaffected. This suggested that the C-
terminus of RNase E is involved in degradation and not rRNA processing (Lopez and others 
1999). Once assembled, the degradosome functions in degradation of 16S, 23S, and 5S rRNA. 
Evidence has shown that the cleavage associated with the degradosome is due to RNase  E 
cleavage and not the ribonucleolytic cleavage activity of PNPase (Bessarab and others 1998). E. 
coli cells deficient for RNase E have been found to be hypersensitive to erythromycin. These 
cells also have a 70% reduction in the 50S ribosomal subunit and an increase in 50S precursor in 
the presence of the antibiotic. These data indicate that RNase E plays an important role in 
degradation of antibiotic impaired ribosomal subunits (Usary and Champney 2001). 
 Studies have shown that in addition to degradation, RNase E is involved in maturation of 
rRNA (Figure 1.7). RNase E, along with RNase G, has been implemented in the cleavage of E. 
coli 16S rRNA. The enzyme removed 115 nucleotides from the 5’ terminus of the rRNA 
precursor to produce a mature 16S rRNA 5’ end (Li and others 1999; Wachi and others 1999). 
RNase E is involved in the maturation of 5S rRNA by cleaving both the 3’ and 5’ termini 
(Arraiano and others 2010; Gutgsell and Jain 2012). In α-proteobacteria, RNase E has been 
implicated in the processing of 23S rRNA at the 5’ end. This processing occurs at helix 9 
following the initial cleavage by RNase III (Klein and Evguenieva-Hackenberg 2002). It stands 
to reason that RNase E might be involved in 23S rRNA processing in other gram negative 
bacteria similar to that of α-proteobacteria. However, no evidence has been published to-date. 
Taken together, the data demonstrate that during rRNA maturation, RNase E is an essential 
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ribonuclease that processes 16S and 5S rRNA. Some research also indicates an involvement in 
23S rRNA maturation, depending on the bacteria. Furthermore, research has revealed an 
importance of RNase E in rRNA degradation (Bessarab and others 1998).  
 
RNase G 
 RNase G is an endoribonuclease homolog of RNase E and has been shown to act similarly 
to RNase E (Tock and others 2000). Like RNase E, RNase G is involved in the maturation of the 
5’ end of 16S rRNA. Strains deficient for RNase G lack a mature 5’ end of 16S rRNA but retain 
a mature 3’ end. Without the mature 5’ end of 16S rRNA, translational function is decreased (Li 
and others 1999; Roy-Chaudhuri and others 2010). In strains that are deficient for RNase G, 
there is an accumulation of a 16S rRNA precursor. These data further indicate that without 
RNase G, 16S rRNA cannot be processed correctly. While RNase E and RNase G are similar 
ribonucleases, they have different recognition sites on the rRNA as indicated in Figure 1.7 
(Wachi and others 1999). Studies have shown that the cleavage of the 5’ terminus of the rRNA is 
accelerated by a monophosphate residue that serves to stimulate RNase G (Jiang and Belasco 
2004). RNase G is also involved in the processing of 23S rRNA, where it functions by 
processing the 5’ end of the ribosomal RNA (Song and others 2011). Taken together, these 
studies show that RNase G functions to process 16S and 23S rRNA at the 5’ end but, unlike 
RNase E, has not been shown to function in RNA degradation.  
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RNase R 
 RNase R is a 3’-5’ exoribonuclease encoded by the rnr gene. RNase R is responsible for the 
degradation of 16S and 23S rRNA; however, it does not degrade 5S rRNA very well (Cheng and 
Deutscher 2002). This enzyme has been shown to increase during conditions of stress and is 
involved in pathogenesis by various microorganisms (Chen and Deutscher 2010; Matos and 
others 2009). When E. coli cells lack both PNPase and RNase R, the cells are no longer viable. 
Due to the fact that cells deficient for RNases R and PNPase are not viable, it is possible that 
these two ribonucleases are a common function that is essential for cell survival. This common 
function might be the degradation and turnover of rRNA. Cells lacking PNPase and RNase R 
showed an increase in 16S and 23S rRNA fragmentation. It has been suggested that this 
accumulation of RNA fragments is lethal to the bacterial cell (Cheng and Deutscher 2003).  
 RNase R degrades RNA fragments by binding to a 3’ terminal overhang of at least seven 
nucleotides (Vincent and Deutscher 2006). It is the only ribonuclease that has been found to 
degrade double stranded RNA without the help of a helicase, provided that the 3’ end overhang 
is single-stranded. Research has also demonstrated that RNA must thread through the RNase R 
protein before degradation can occur, indicating that the enzyme does not merely attach to RNA 
to begin degradation. RNase R does not degrade RNA via the 5’ end. It has been determined that 
the RNB domain or C-terminal of the enzyme is essential for RNA degradation. This domain is 
crucial because of Asp
280
, which must be present for degradation to occur. This amino acid 
contributes to the ribonuclease’s ability to degrade RNA but not to the binding of RNA (Matos 
and others 2009; Vincent and Deutscher 2006).  
 As previously stated, many RNases are regulated by the presence or absence of other 
RNases. The cleavage of the rnr gene is regulated by RNase E. When RNase E is absent or 
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down-regulated in cells, the rnr operon stability is increased and RNase R protein is increased. 
This increased stability and protein production is possibly due to the lack of the degradosome 
(Cairrão and Arraiano 2006). These data further demonstrate the close connection and regulation 
of various bacterial ribonucleases. In addition to its regulation by RNase E, RNase R bears a 
resemblance to RNase II. The two enzymes share a 60% homology with each other. PNPase, 
RNase R and RNase II are the three major exoribonucleases in a bacterial cell (Awano and others 
2010; Matos and others 2011).  
 RNase R is up-regulated in a cell during stress, such as starvation or dramatic temperature 
changes. Under conditions of stress, the enzyme is stabilized; however, during the normal 
exponential phase of cellular growth RNase R is very unstable. This raises the possibility that the 
cell increases RNase R during times of stress to degrade damaged ribosomal RNA but is not used 
as much for quality control purposes (Chen and Deutscher 2005; 2010). This RNase R-mediated 
degradation of rRNA during stress may be important since an accumulation of fragmented RNA 
can be toxic to the bacterial cell.  
 
RNase II 
 Like RNase R, RNase II is a 3’-5’ exoribonuclease. It is encoded by the rnb gene (Matos 
and others 2011). RNase II is thought to be involved in the removal of the poly (A) tail to protect 
mRNA from degradation and its presence has been shown to be regulated by PNPase. RNase III 
and RNase E indirectly affect RNase II by modulating PNPase and degrading RNase II mRNA 
respectively (Arraiano and others 2010; Zilhão and others 1995).  RNase II is able to bind both 
DNA and RNA but distinguishes between the two based on the Tyr
313
 and Glu
390
 of the enzyme. 
Tyr
313
 of RNase II is responsible for the recognition of RNA, and Glu
390
 of RNase II is 
33 
 
responsible for recognition of DNA. For RNA degradation to occur, Asp
209
 of the enzyme must 
be present. This exoribonuclease has been shown to become a “super enzyme” when a site-
directed mutation occurs that converts Glu
542
 to Ala
542
. Once converted to a super enzyme, 
exoribonucleolytic cleavage is increased approximately 100-fold and RNA binding is increased 
by about 20-fold (Arraiano and others 2010; Matos and others 2011; Zuo and Deutscher 2001).  
 Under normal circumstances, RNase II is involved in both rRNA maturation and 
degradation. It has been documented that when RNase II is absent from E. coli cells, there is an 
accumulation of the 30S and 50S ribosomal precursors (Corte and others 1971). The data also 
showed an increase in the 16S rRNA precursor, 17S rRNA, when RNase II was inactive. These 
results indicated a role of RNase II in ribosomal precursor maturation and in the maturation of 
17S to 16S rRNA (Corte and others 1971). Studies have shown that E. coli cells deficient for 
RNase II display a large reduction in the formation of the 50S subunit and an increase in 23S 
rRNA fragmentation (Silvers and Champney 2005). Taken together, these data indicate a role in 
maturation of 16S rRNA and the degradation and turnover of 23S rRNA.  
 Silvers and Champney found that E. coli cells deficient for RNase II demonstrated a 
decrease in the 50S ribosomal subunit amounts and an increase in 23S rRNA when the macrolide 
antibiotic, azithromycin, was present. Further research revealed that when azithromycin was 
removed, there was a significantly reduced rate of recovery in these cells. These data indicated 
that RNase II is important to the degradation and turnover of antibiotic-stalled ribosomes (Silvers 
and Champney 2005).   
 RNase II and RNase R are homologs of each other and share approximately 60% 
similarities. These enzymes do, however, have a few key differences. One difference between 
these two members of the RNase II super family is the type of final end product that is released. 
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For its final product, RNase II releases a fragment of four nucleotides in length. RNase R 
releases a two nucleotide fragment. This difference is due to the aromatic amino acid locations in 
the RNase. For RNase II, Tyr
253
 and Phe
358
 lock onto the RNA. Tyr
253
 is responsible for 
determining the end fragment size. For RNase R, Tyr
324
 and Phe
429
 lock onto the RNA and Tyr
324
 
is responsible for the end fragment size. While Tyr
324 
is responsible for determining fragment 
size, studies have shown that the position of the phenylalanine determines how tightly the 
enzyme fastens onto the RNA. The final end product is an important distinction because studies 
have shown that the four nucleotide product must be further degraded to a two nucleotide 
product in order to be recycled (Matos and others 2009; Matos and others 2011). Another 
important difference between the two enzymes is the C-terminal tail. RNase R does not need the 
assistance of a helicase in order to degrade RNA while RNase II does. This is due to the presence 
of a lysine-rich C-terminal tail in RNase R that is not found in RNase II (Matos and others 2011). 
These differences are important distinctions between two degradative ribonucleases and further 
exemplify their functions. 
 
PNPase 
 Polynucleotide phosphorylase (PNPase) is a 3’-5’ exoribonuclease and, along with RNase 
PH, is a member of the PDX family (Arraiano and others 2010). PNPase is encoded by the pnp 
gene and functions solely in RNA degradation. This enzyme is part of a larger complex in 
bacterial cells, known as the degradosome (Mohanty and Kushner 2003). When a bacterial cell is 
deficient for RNase II or RNase III, PNPase levels are increased. PNPase functions to regulate 
RNase II by degrading the RNase II mRNA (Arraiano and others 2010). Studies have found that 
RNase E has a direct interaction with PNPase, enolase, and RhlB. While PNPase appears to bind 
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with RhlB, there does not appear to be any direct binding of PNPase with enolase and the 
interaction must occur through RNase E (Burger and others 2011). 
 PNPase and RNase PH are the only RNases that require a phosphate group at the end of the 
RNA group in order to break the phosphodiester bond and cleave the RNA (Zhou and Deutscher 
1997). In order to begin the process of degradation, a single stranded RNA must have an RNA 
overhang that ranges from 7-10 nucleotides in length at the 3’ end (Arraiano and others 2010). E. 
coli cells deficient for PNPase have been shown to have an accumulation of 23S rRNA in the 
presence of azithromycin and a reduced recovery rate when the antibiotic was removed. This 
information indicates an importance of PNPase in rRNA degradation when an antibiotic is 
present (Silvers and Champney 2005). 
 In E. coli cells deficient for RNase R and temperature sensitive for PNPase, there is a large 
accumulation of 16S and 23S rRNA, suggesting that these two enzymes play a key role in the 
degradation and turnover of this RNA (Zhou and Deutscher 1997). E. coli cells deficient for both 
PNPase and RNase PH grow much slower than wild type E. coli cells. These cells also show a 
decrease in the 50S ribosomal subunit and an increase in RNA degradation products 
sedimentating in sucrose gradients between 4S and 16S. These results suggest that the subunit is 
unable to assemble correctly which leaves the rRNA susceptible to degradation (Zhou and 
Deutscher 1997). 
 
RNase PH 
 RNase PH is a 3’-5’ exoribonuclease belonging to the PDX family (Arraiano and others 
2010; Worrall and Luisi 2007). This enzyme binds to the last 4 nucleotides of single stranded 
RNA to begin degradation (Lorentzen and Conti 2005). RNase PH has been shown to be 
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involved in tRNA maturation; however studies are revealing an increasingly important role of 
the enzyme in rRNA degradation and maturation. RNase PH has been implicated in rRNA 
degradation during starvation, and it has been shown that the degradation of 16S rRNA at the 3’ 
terminus is facilitated by RNase PH (Basturea and others 2011). Studies have found that the 
deletion of RNase II and RNase PH or the deletion of RNase PH and PNPase results in a large 
increase in the 23S rRNA precursor. Analysis of the RNA in these cells revealed unprocessed 
nucleotides of the 23S rRNA that are approximately 5-6 nucleotides in length (Gutgsell and Jain 
2012). RNase PH was concluded to be the ribonuclease preferred to cleave 23S rRNA due to the 
following factors. First is that in the precursor form, 23S rRNA 3’ end has a short overhang of 
approximately three nucleotides followed by base pairing with the 5’ end. RNase II and PNPase 
are not as effective as RNase PH at cleaving this region. Second, the presence of two cytosines at 
the 3’ end of 23S rRNA, which inhibit final rRNA maturation by RNase T. Together, these data 
show that RNase PH can initiate maturation by cleavage of the duplex region and removal of the 
CC sequence. This then allows RNase T to cleave and mature the 3’ end of 23S rRNA (Gutgsell 
and Jain 2012). These data point to RNase II and PNPase playing a role in 23S rRNA 
degradation and also indicate that RNase PH plays a pivotal role in this process.  
 In summary, the eight RNases shown in Table 1.2 have been found to function in rRNA 
maturation and degradation. Various studies have indicated increasingly important roles of 
RNases when antibiotics are present (Silvers and Champney 2005; Usary and Champney 2001). 
However, ribonuclease deficient mutants are not naturally occurring. Treatment with an RNase 
inhibitor might act to mimic the results seen with various RNase deficient mutant bacteria, and 
potentially provide a novel mechanism for increasing the effectiveness of antibiotics which act 
by blocking ribosome assembly. 
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Vanadyl Ribonucleoside Complex 
 Vanadyl ribonucleoside complex (VRC) is a RNase inhibitor. This complex is commonly 
used to reduce RNA degradation during the isolation of RNA (Berger 1987; Berger and others 
1980). While it is unknown which RNases are inhibited, it is theorized that VRC functions to 
inhibit endoribonucleases (Berger 1987). Lee et al. found that 10mM VRC inhibited recombinant 
RNase H activity by 90% (Lee and others 1997). To-date, there has been no published research 
indicating the use of RNase inhibitors to inhibit ribonuclease function in a cellular system. 
Previous data has shown that E. coli cells deficient for RNases are more susceptible to antibiotics 
(Silvers and Champney 2005; Usary and Champney 2001). It is possible that the use of an RNase 
inhibitor to inhibit bacterial RNases in the cell would serve as a novel antibiotic therapy. 
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Research Hypothesis 
 Many current antibiotics operate by inhibiting the assembly of the bacterial ribosome 
(Champney 2003; Champney and Burdine 1998a; Champney and Miller 2002; Champney and 
Rodgers 2007; Champney and Tober 2000; Chittum and Champney 1995; Mehta and Champney 
2002; 2003). It is known that ribonucleases play an important role in bacterial ribosomal subunit 
assembly (Awano and others 2010; Gutgsell and Jain 2012; King and others 1984; Klein and 
Evguenieva-Hackenberg 2002; Li and others 1999; Song and others 2011; Xiao and others 
2009). RNases also play a key role in rRNA degradation. When an inhibitor such as an antibiotic 
is introduced to the bacterial cell, under normal circumstances, RNases function to degrade the 
ribosomal precursors and to allow the rRNA nucleotides to be recycled and reused (Figure 1.6).  
Previous research has shown that when E. coli cells are deficient for RNases II, E, or PNPase, 
these cells display a hypersensitivity to azithromycin (Silvers and Champney 2005).  
 It is hypothesized that the loss of RNases will increase the sensitivity of E. coli to 
aminoglycoside antibiotics, neomycin and paromomycin. Aminoglycoside antibiotics are chosen 
for this research study because, like macrolides, they function by blocking 50S subunit assembly. 
However, unlike macrolides, aminoglycosides also block 30S subunit assembly (Campuzano and 
others 1979; Foster and Champney 2008; Mehta and Champney 2002; Silvers and Champney 
2005; Tenson and Mankin 2006). The E. coli mutants that are found in this study to have an 
increased sensitivity to aminoglycosides are not found in nature. Therefore, I want to determine 
if a RNase inhibitor can be used to mimic the enhanced antibiotic sensitivity of RNase mutant E. 
coli cells. It is hypothesized that an inhibitor of ribonucleases can inhibit bacterial RNases and 
potentiate the effects of both a macrolide antibiotic and an aminoglycoside antibiotic.  
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Specific Research Aims 
Aim 1: To determine whether RNase deficient Escherichia coli cells will display increased 
sensitivity to aminoglycoside antibiotics. Results are found in Chapter 2 
 Frazier, A. D., and W. S. Champney. 2012. Inhibition of ribosomal subunit synthesis in 
 aminoglycoside treated ribonuclease mutants of Escherichia coli. Archives of 
 Microbiology:In Submission. 
 
Aim 2: To determine whether the use of vanadyl ribonucleoside complex will potentiate the 
effects of an aminoglycoside and a macrolide in wild type Escherichia coli cells. Results are 
found in Chapter 3  
 “Inhibition of Ribosomal Subunit Synthesis in Escherichia coli by the Vanadyl 
 Ribonucleoside Complex”  
 
Aim 3: To determine whether the use of vanadyl ribonucleoside complex will potentiate the 
effects of an aminoglycoside and a macrolide in methicillin sensitive and methicillin resistant 
Staphylococcus aureus cells. Results are found in Chapter 4  
 Frazier, A. D., and W. S. Champney. 2012. The vanadyl ribonucleoside complex inhibits 
 ribosomal subunit formation in Staphylococcus aureus. Journal of Antimicrobial 
 Chemotherapy:In Submission. 
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Abstract The bacterial ribosome is a major target for current antibiotic therapy. During 
ribosomal subunit biogenesis, ribonucleases (RNases) play an important role in rRNA 
processing. Aminoglycoside antibiotics bind to both 30S and 50S subunits and stall subunit 
assembly.  E. coli cells deficient for specific RNases are predicted to have an increased 
sensitivity to neomycin and paromomycin.  It is shown that E. coli strains deficient for the rRNA 
processing enzymes RNase III, RNase E, RNase R, RNase G, or RNase PH have enhanced 
subunit assembly defects. These mutants showed an increased sensitivity to both aminoglycoside 
antibiotics. An increase in 16S and 23S rRNA fragmentation was detected in E. coli cells 
deficient for these enzymes. This research identified ribonucleases involved in rRNA processing 
as important in the effectiveness of aminoglycoside inhibition.  
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Introduction  
Resistance to the most commonly used antimicrobial agents is increasing. Well examined 
mechanisms include acquisition of resistance genes, up-regulation of genes encoding cellular 
efflux pumps and spontaneous mutations in target genes (Zinner 2007). Development of novel 
antibacterial agents and the identification of additional bacterial targets have become important 
research endeavors. 
 One important target of many antibiotics is the bacterial ribosome (Wallis and Schroeder 
1997; Champney 2006). The prokaryotic ribosome consists of a large 50S and a small 30S 
subunit. The 50S subunit is composed of 23S and 5S rRNA and 34 proteins. 30S subunits 
contain 16S ribosomal RNA and 21 proteins. During subunit biogenesis, 16S, 23S, and 5S rRNA 
transcripts and ribosomal proteins combine to form intermediate precursors. The rRNA in the 
precursor particles is cleaved by endo- and exoribonucleases to produce the mature subunits 
(Kaczanowska and Rydén-Aulin 2007; Deutscher 2009). In addition to maturation, ribonucleases 
(RNases) are involved in degradation of rRNA. When an inhibitor, such as an antibiotic, is 
introduced into a bacterial cell during ribosomal formation, specific RNases are utilized to 
degrade the rRNA to eliminate the stalled precursor (Champney 2006). 
 Some antibiotics function by targeting both the 30S and 50S subunits. Neomycin and 
paromomycin are two aminoglycoside antibiotics that have been shown to inhibit 30S subunit 
assembly in various bacteria, including E. coli and Staphylococcus aureus (Mehta and 
Champney 2002; Mehta and Champney 2003). These antibiotics bind to helix 44 of 16S rRNA 
and stimulate mistranslation of mRNA. Aminoglycosides also bind to helix 69 of 23S rRNA. By 
binding to helix 69, the ability of the ribosome recycling factor to recycle the ribosome is 
inhibited. It can be postulated, based on previous research, that the binding of aminoglycosides 
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to Helix 69 inhibits the ribosome recycling factor from dissociating the 30S and 50S ribosomal 
subunits and recycling the ribosome (Hirokawa et al. 2005; Borovinskaya et al. 2007; 
Scheunemann et al. 2010). 
 This important role of RNases in rRNA processing and subunit assembly makes these 
enzymes potential targets for novel antibiotics. It has been previously shown that strains of E. 
coli deficient for RNase E, RNase II, or polynucleotide phosphorylase (PNPase) displayed an 
increased sensitivity to erythromycin or azithromycin (Usary and Champney 2001; Silvers and 
Champney 2005). These mutant E. coli strains also demonstrated an accumulation of 23S rRNA 
and a reduced rate of recovery when the antibiotic was removed.  The importance of RNases in 
rRNA processing led us to propose that mutant E. coli strains would also be  more sensitive to 
aminoglycosides. This work shows that E. coli strains deficient for RNase III, RNase E, RNase 
R, RNase G, or RNase PH have an increased sensitivity to neomycin and paromomycin, 
reflected in reduced subunit synthesis and enhanced rRNA turnover. 
 
 
Materials and methods 
Analysis of cellular growth and viability 
 
Escherichia coli strains that were used are listed in Table 2.1. Cultures were grown at 37
o
C (or 
32
o
C for ts mutants) in tryptic soy broth (TSB). Strains SK5665, SK5729, SK6639 and SK7622 
were supplemented with 4g/mL thymidine. Growth rates were measured as an increase in 
cellular density over time using a Klett-Summerson colorimeter. At a Klett reading of 20, 
neomycin or paromomycin at 5 or 10µg/mL were added to the appropriate cultures. At a Klett 
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reading of 80, cellular viability was determined by TSB agar plate colony counting after serial 
dilutions (Jett et al. 1997).  
 
Analysis of ribosomal subunit assembly 
 
Cell cultures were grown in TSB as described. At a Klett reading of 20, neomycin or 
paromomycin at 5µg/mL were added to the appropriate cultures. After 15 minutes of growth 
with the antibiotics, 
3
H uridine (30 Ci/mmol, Am. Radiochemicals) at a concentration of 
1µCi/mL and uridine at a concentration of 2µg/mL were added. The cells were allowed to grow 
for two cellular doublings. At that time, uridine was added to 50µg/mL and the cells were 
incubated for an additional 15 minutes. Cells were collected by centrifugation and stored frozen 
at -70
o
C.  
Cellular lysates were prepared with lysozyme and DNaseI as previously described (Silvers 
and Champney 2005).  The samples were centrifuged through 5-20% sucrose gradients in S 
buffer in an SW41 rotor at 187813 x g for 3.5 hours. Following centrifugation, fractions were 
collected by pumping them through an ISCO Model UA-5 absorbance monitor set at 254nm. The 
fractions were collected into vials and mixed with 3mL Scintisafe gel before measuring the 
3
H 
uridine radioactivity by liquid scintillation counting. 
 
Analysis of total cellular RNA with the Agilent Bioanalyzer 
 
Bacterial cells were grown as described above. At a Klett reading of 80 or an approximate 
density of 4x10
8
 cells/mL, the cells were collected by centrifugation and RNA was extracted 
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from the cell pellet. Total RNA from cell samples was isolated by phenol/chloroform extraction 
and ethanol precipitation (Rio et al. 2011). Typically 0.5 to 1µg of RNA was examined using an 
Agilent Bioanalyzer 2100 and the RNA 6000 nano chip.  
 
Table 2.1 E. coli strains used in this study 
 
Strain Phenotype Genotype Reference or source 
SK901 None F- malA thi- (Kushner et al. 1977) 
D10-1 I HfrH met- rna-1 relA (Gesteland 1966) 
SK7622 III F-thyA715 rncD38::kanR (Babitzke et al. 1993) 
SK5665 E  F-thyA715 rne1 (Arraiano et al. 1988) 
SK4803 II F-gal thi ton sup hasdR4 endAsbcB15 rnb296 (Donovan and Kushner 1986) 
N7060 I, II, PNPase 
F- metB1 tryA451 rpsl478 rna919rnb464 
pnp13 
(Weatherford et al. 1972) 
MG1655 I-R- I, R        ∆rna ∆rnr::cam (Chen and Deutscher 2010) 
GW11 G F- zce-726::Tn10, TetR, rng::cat CmR (Li et al. 1999) 
SK6639 PNPase F-thyA715, CmR, pnp-200, rph-1, λ- (Cheng and Deutscher 2003) 
SK5729 I, II, PNPase, PH 
     F- thyA715, rna-19, rnb-500, pnp-7, λ-, 
rph-1 
 Sidney Kushner  
 
 
 
Analysis of 16S rRNA and 23S rRNA by Northern blot hybridization 
 
Biotinylated 16S and 23S specific probes were constructed as previously described (Silvers and 
Champney 2005). The 16S (241 bp) and 23S (146 bp) DNA probes were amplified from plasmid 
pKK3535 DNA (Brosius et al. 1980) using the polymerase chain reaction. The 23S primers used 
were 23S F: TAG GGG AGC GTT CTG TAA G and 23S R: CCC ATT AAC GTT GGA C (nt. 
nos. 1188-1334). The 16S primers used were 16S F: GGA GGA AGG TGG GGA TGA CG and 
16S R: ATG GTG ACG GGC GGT GTG (nt. nos. 1173-1414). The primers were from Life 
Technologies. PCR products were purified by extraction with equal amounts of phenol and 
chloroform before precipitating with 2 volumes of ethanol. The pellets were resuspended in 
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30µL of sterile water. The purified DNA probes were labeled with biotin using the Label-IT 
biotin labeling kit (Mirus) per the manufacturer’s instructions (Silvers and Champney 2005). 
 Six micrograms of total RNA was denatured by heating at 55
o
C for 10 minutes and 
separated on a 5% TAE PAGE gel as previously described (Rio et al 2011). After destaining 
overnight in sterile water, RNA was transferred onto Nytran nylon membranes using a Turbo 
blot apparatus (Schleicher & Schuell). The membranes were pre-hybridized in 15mL of 1X pre-
hybridization solution (MRC, Inc.) at 42
o
C for 30 minutes. The membranes were then hybridized 
overnight at 42
o
C with 6mL hybridization buffer (50% formamide, 5X SSC, 0.1% sarkosyl, 
0.02% SDS and 200µg/mL BSA), 1X background quencher (MRC, Inc.), and 4pmol of the 
denatured 16S or 23S specific probe (Silvers and Champney 2005). After hybridization, the 
membranes were washed and the probe detected with horseradish peroxidase using the 
North2South chemiluminescent hybridization kit (Pierce Chemical Co.). Analysis of the rRNA 
fragmentation was conducted by image analysis in the G Box Imager (SynGene).  
 
Statistical analysis 
 
 Statistical differences were determined using Student t-test. Each wild type or RNase 
deficient mutant sample incubated with an antibiotic was compared to the control cells without 
antibiotics for that RNase strain. In each table, an asterisk indicates a statistical significance of 
P<0.05.  
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Results 
 An initial test was performed to determine whether E. coli mutants deficient for any of eight 
RNases would show an enhanced sensitivity to the aminoglycosides, neomycin and 
paromomycin. Previous research has shown that strains missing RNase II, E or PNPase 
demonstrated an increased sensitivity to the macrolide antibiotic azithromycin (Silvers and 
Champney 2005). As Table 2.2 shows, strains missing the rRNA processing enzymes RNase III, 
E, R, G or PH revealed a large reduction in viability after growth with either aminoglycoside. All 
the percentages were determined by comparing the antibiotic treated samples with that strain’s 
control.  In particular, neomycin at 10µg/mL reduced the viability of RNase III, E, R, or PH 
mutants to approximately 10% of the untreated control strain (Table 2.2).  
 
 
Table 2.2 Effect of aminoglycosides on viability of wild type and mutant E. coli cells 
 
  % Control total viable cell count 
Strain RNase mutation Neomycin Paromomycin 
  5µg/mL 10µg/mL 5µg/mL 10µg/mL 
SK901 None 15.4±12.8  26.3±9.0      7.7±5.1          3.0±0.5 * 
D10-1 I   18.2±5.0  14.2±4.1  20.7±19.8  17.4±17.4 
SK7622  III   0.32±0.001 *       5.7±4.2 *         4.6±3.5 *          2.5±1.2 * 
SK5665 E 51.9±33.4       3.6±0.4 *       12.5±8.4 *    0.89±0.001 * 
SK4803 II 44.4±25.9    5.2±4.9    11.1±3.3      1.1±0.9 
N7060 I, II, PNPase         5.2±5.0 *       6.1±2.4 *  33.5±15.8         3.3±0.2 * 
MG1655 I
-
R
-
 I, R       13.4±7.5 *     11.5±7.3 *         5.1±1.5 *         4.2±0.4 * 
GW11 G       10.6±7.1 *     23.2±8.8 *       10.7±6.3 *         2.4±0.9 * 
SK6639 PNPase  75.4±21.1       5.2±1.8 *    51.4±4.9         3.2±0.7 * 
SK5729 I, II, PNPase, PH  80.0±39.3       3.0±1.9 *       15.0±6.1 *         2.0±0.6 * 
Results are the means ± standard error of 4 independent experiments. (*) statistically significant 
with a P value <0.05 
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 Aminoglycoside antibiotics can bind to both 30S and 50S ribosomal subunits (Borovinskaya 
et al. 2007; Scheunemann et al. 2010).  Therefore, the mutants deficient for RNase I, E, III, R, G, 
PH or a combination of mutations were examined for impaired 30S and 50S ribosomal subunit 
assembly. E. coli deficient for more than one mutation (N7060) were also included in 
determining impairment of 30S and 50S ribosomal subunit assembly. This is because we wanted 
to show that the decrease in 30S and 50S subunit assembly for MG1655 I
-
R
- 
and SK5729 was 
due to RNase R and RNase PH deficiencies respectively. Cells were labeled with 
3
H-uridine 
during growth without and with antibiotics.  Ribosomal subunit amounts were measured after 
separation by sucrose gradient centrifugation. Figure 2.1 shows the gradient profiles for each 
selected strain.  Both aminoglycosides promoted a reduction in 30S subunit amounts in most of 
the RNase mutant E. coli strains. 50S subunit levels were reduced in every case after drug 
treatment except in the wild type and RNase G deficient strains. Significantly, a major increase 
in labeled RNA was seen in the top gradient fractions (Table 2.3), indicative of rRNA 
degradation (Silvers and Champney 2005). For example the RNase E mutant strain showed a 14 
and 24% increase in labeled RNA at the top of the gradient when neomycin or paromomycin 
where added at a concentration of 5µg/mL. E. coli deficient for RNase PH showed a 10% 
decrease in the 30S ribosomal subunit when either antibiotic was added. Additionally, the 50S 
ribosomal subunit was decreased by 5 and 13% when 5µ/mL neomycin or paromomycin were 
added. In every case, the labeled RNA lost from the subunits was accounted for by an 
approximate amount present in the top gradient region. Strain N7060 is deficient for RNases I, II, 
and PNPase. Due to the findings that this strain displayed a decrease in 30S and 50S ribosomal 
subunits (Table 2.3), it was determined that any statistical significance found in strain SK5729 is 
due to the loss of RNase PH and not to the other mutations. 
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Fig. 2.1 Sucrose gradient profiles of 
3
H uridine labeled ribosomal subunits isolated from E. coli 
cells grown with or without 5µg/mL antibiotics. Gradient profiles for wild type (A), RNase III 
deficient (B), RNase E deficient (C), RNase R deficient (D), RNase G deficient (E), and RNase 
PH deficient (F) 
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Table 2.3 Distribution of 
3
H uridine labeled RNA in sucrose gradient regions 
 
  % Total gradient radioactivity 
Strain 
RNase 
mutation 
Control Neomycin Paromomycin 
  Top 30S 50S Top 30S 50S Top 30S 50S 
SK901 None 29.01±0.5 24.84±1.1 43.09±0.3 
47.52±0.5 
(166.8) * 
24.63±1.3 
(105.9) 
20.27±1.0 
(47.0) * 
42.80±2.2 
(149.2) * 
23.74±0.7 
(95.6) 
27.85±0.5 
(66.9) * 
D10-1 I 27.92±3.1 22.94±0.8 45.57±1.8 
45.52±5.0 
(163.0) 
22.49±2.0 
(105.1) 
27.55±8.4 
(62.8) 
40.32±8.6 
(146.7) 
19.32±3.2 
(84.2) 
35.49±6.1 
(79.7) 
SK7622 III 23.99±1.3 23.84±0.5 48.70±.05 
44.06±6.3 
(187.0) 
23.73±3.2 
(99.5) 
24.93±3.9 
(51.2) * 
41.95±2.7 
(176.7) * 
22.57±1.1 
(94.7) 
30.37±3.2 
(62.4) * 
SK5665 E 31.55±0.9 23.97±0.4 40.57±1.4 
47.61±6.6 
(150.9) 
20.07±1.0 
(83.7)* 
27.83±5.5 
(68.6) 
37.64±3.8 
(119.3) 
27.12±4.5 
(113.1) 
33.78±2.6 
(83.3) 
N7060 I, II, PNPase 25.60±1.6 25.41±0.06 46.15±2.9 
37.12±2.7 
(145.0) 
22.20±1.1 
(87.4) 
36.92±3.9 
(80.0) 
24.78±1.8 
(96.8) 
21.50±0.1 
(84.6)* 
45.77±0.06 
(99.2) 
MG1655I-R- I, R 30.28±1.0 24.37±0.4 41.56±1.5 
44.98±6.2 
(148.5) 
22.05±1.9 
(90.5) 
28.76±5.4 
(69.2) 
34.40±2.9 
(113.6) 
24.32±0.9 
(99.8) 
37.48±4.0 
(90.2) 
GW11 G 29.04±2.4 24.75±1.5 43.38±1.6 
42.28±1.8 
(145.6) * 
19.79±0.8 
(80.0) 
26.48±2.8 
(61.0) 
33.34±1.7 
(114.8) 
23.74±0.005 
(95.9) 
40.00±2.1 
(92.2) 
SK5729 
I, II, 
PNPase, PH 
38.31±1.9 26.42±3.8 31.78±2.6 
62.42±4.4 
(162.9) * 
16.85±0.7 
(63.8) 
16.47±3.6 
(51.8) * 
62.03±3.0 
(161.9) * 
17.31±1.0 
(65.5) 
15.46±2.3 
(48.6) * 
Cells were grown with 5µg/mL aminoglycosides. Radioactivity in gradient fractions corresponding to the top, 30S, and 50S regions 
were summed and calculated as a percent of the total radioactivity in the gradients. Percentage of the 30S and 50S regions in 
comparison to the mutant or wild type strain controls is shown. Results are the means ± standard error of 2 independent experiments. 
(*) statistically significant with a P value <0.05
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 Total RNA was isolated from each selected strain after growth without and with the 
aminoglycosides, and the status of rRNA in all cells was examined by Agilent chip analysis. An 
enhanced rRNA degradation was observed in the mutants, particularly after growth with the 
antibiotics at 10µg/mL (Figure 2.2 and Table 2.4). In addition, RNase R and RNase PH mutant 
strains displayed an increase in small RNA oligonucleotides. As with the gradient rRNA 
distribution, the loss of 16S and 23S rRNA could be accounted for by an increase in small RNA 
species. For example, the RNase PH mutant strain’s small RNA was increased by more than 
130% when either antibiotic was added at 10µg/mL. In the RNase R mutant strain, 16S rRNA 
was decreased by 19-23% when neomycin or paromomycin were added at a concentration of 
10µg/mL. The RNase PH deficient strain showed a 35% and 16% decrease in 23S rRNA when 
either neomycin or paromomycin were added at a 10µg/mL concentration (Table 2.4). Finally, 
the analysis revealed the accumulation of a band the approximate size of 16S precursor RNA in 
all mutant strains with the exception of the RNase G deficient strain. This 16S precursor band 
can be seen directly above the 16S band in the Agilent gel image (Figure 2.2).  
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Fig. 2.2 Agilent gel analysis of total RNA. RNA samples were analyzed by the Agilent 
Bioanalyzer. Agilent chip analysis of RNA from wild type and mutant cells grown with 5µg/mL 
antibiotics (a) and (b). Agilent chip analysis of RNA from wild type and mutant cells grown with 
10µg/mL antibiotics (c) and (d). Control (C), Neomycin (N), Paromomycin (P) 
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Table 2.4 Percentage distribution of small, 16S, and 23S rRNA by Agilent gel analysis 
 
 % Total area 
Strain RNase 
mutation 
Control Neomycin 5µg/mL Paromomycin 5µg/mL 
  RIN Small 16S 23S RIN Small 16S 23S RIN Small 16S 23S 
SK901 None 9.8± 
0.1 
11.53± 
4.4 
26.80±1.3 40.80±3.2 9.5±2.3 
(96.9) 
17.37±4.7 
(150.7) 
23.03±1.3 
(85.9) 
38.87±2.7 
(95.3) 
8.7±0.8 
(88.5) 
18.83±3.2 
(163.3) 
23.78±1.4 
(88.7) 
34.70±1.9 
(85.0) 
SK7622 III 8.8± 
1.1 
17.87±6.6 29.73±3.3 44.27±5.3 8.8±1.0 
(100.0) 
12.80±5.3 
(71.6) 
30.93±5.2 
(104.0) 
46.73±4.1 
(105.6) 
9.2±0.7 
(104.5) 
14.90±3.1 
(83.4) 
37.37±11.2 
(125.7) 
33.97±8.9 
(76.7) 
SK5665 E 8.8± 
0.8 
17.50±6.9 22.85±3.6 36.60±6.7 9.3±0.3 
(105.7) 
15.10±5.3 
(86.3) 
24.00±2.8 
(105.0) 
37.38±4.1 
(102.1) 
9.3±0.3 
(105.7) 
19.18±7.0 
(109.6) 
25.55±2.0 
(111.8) 
39.70±2.8 
(108.5) 
MG1655 
I
-
R
-
 
I, R 9.1± 
0.5 
13.80±3.4 19.80±2.4 32.57±6.7 8.2±0.8 
(90.1) 
15.83±3.5 
(114.7) 
15.50±4.7 
(78.3) 
26.07±8.3 
(80.0) 
9.0±0.1 
(98.9) 
17.57±1.2 
(127.3) 
19.77±1.3 
(99.8) 
33.23±2.8 
(102.0) 
GW11 G 9.7± 
0.1 
18.00±2.3 23.50±1.0 34.47±1.8 9.4±0.1 
(96.9) 
17.03±3.7 
(94.6) 
21.33±0.7 
(90.8) 
33.37±1.6 
(96.8) 
8.5±0.9 
(87.6) 
20.73±3.8 
(115.2) 
17.97±4.3 
(76.5) 
26.70±6.9 
(77.5) 
SK5729 I, II, 
PNPase, 
PH 
6.6± 
0.005 
24.20±0.2 14.40±0.1 19.35±0.7 7.0±0.1 
(106.1) * 
29.70±0.2 
(122.7) * 
15.65±0.1 
(108.7) * 
20.10±0.3 
(103.9) 
6.8± 
0.005 
(103.0) * 
34.90±2.0 
(144.2) * 
12.70±0.1 
(88.2) * 
15.25±0.3 
(78.8) * 
      
 % Total area 
Strain RNase 
mutation 
Control Neomycin 10µg/mL Paromomycin 10µg/mL 
  RIN Small 16S 23S RIN Small 16S 23S RIN Small 16S 23S 
SK901 None 9.5± 
0.2 
12.05±0.2 24.40±1.0 42.10±3.7 9.8±0.2 
(103.4) 
13.70±0.7 
(113.7) 
26.85±4.55 
(110.0) 
44.25±4.5 
(105.1) 
8.8±1.3 
(92.6) 
20.10±3.7 
(166.8) 
28.00±3.2 
(114.8) 
44.00±3.6 
(104.5) 
SK7622 III 9.0± 
0.4 
16.25±1.5 23.35±0.9 32.50±1.0 7.7±1.4 
(85.6) 
20.55±1.1 
(126.5) 
23.50±1.5 
(100.6) 
38.90±9.8 
(119.7) 
9.4±0.2 
(104.4) 
17.10±0.1 
(105.2) 
23.25±0.6 
(99.6) 
34.00±4.5 
(104.6) 
SK5665 E 10.0± 
0.1 
6.60±0.4 27.70±1.0 48.10±5.6 9.2±0.005 
(92.0) 
5.10±0.9 
(77.3) 
23.8±0.8 
(85.9) 
40.85±2.8 
(84.9) 
9.3±0.1 
(93.0) 
9.45±1.1 
(143.2) 
22.65±0.9 
(81.8) 
37.80±2.2 
(78.6) 
MG1655 
I
-
R
-
 
I, R 9.9± 
0.1 
13.8±1.4 25.4±0.5 43.65±2.65 8.9±0.1 
(89.9) 
13.05±0.3 
(94.6) 
20.55±0.1 
(80.9) * 
40.80±1.3 
(93.5) 
9.0±0.1 
(90.9) 
16.95±0.1 
(122.8) 
19.65±0.4 
(77.4) * 
40.50±1.9 
(92.8) 
GW11 G 9.8± 
0.1 
18.45±2.8 23.65±1.2 34.80±0.6 9.6±0.3 
(98.0) 
15.65±3.3 
(84.8) 
21.80±1.1 
(92.2) 
34.80±2.9 
(100.0) 
9.8±0.3 
(100.0) 
15.20±1.0 
(82.4) 
25.4±2.0 
(107.4) 
40.15±2.3 
(115.4) 
SK5729 I, II, 
PNPase, 
PH 
6.7± 
0.1 
23.50±0.7 13.50±0.7 19.05±0.5 6.1± 
0.005 
(91.0) * 
33.60±0.5 
(143.0) * 
9.45±0.3 
(70.0) * 
12.70±0.4 
(65.1) * 
6.7±0.1 
(100.0) 
31.30±0.2 
(133.2) * 
13.35±0.3 
(98.9) 
15.95±0.2 
(83.7) * 
Total RNA in gel bands from Figure 2.2 was computed by analysis of the electropherograms using Agilent software. Percentage of the 
total RNA in comparison to the wild type or mutant strain controls in each gel region is shown. The RNA integrity number (RIN) is 
indicated. Results are the means ± standard error of 2 independent experiments. (*) statistically significant in comparison to no drug 
controls for each strain with a P value <0.05
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 Degradation of 16S and 23S rRNA stimulated by antibiotic treatment was further examined 
by Northern hybridization analysis. Figure 2.3 shows the result of Northern blots hybridized with 
a 16S rRNA probe, and Figure 2.4 shows the same E. coli samples examined for rRNA 
fragmentation with a 23S rRNA probe. With the exception of the RNase E mutant, enhanced 16S 
rRNA fragmentation was observed (Figure 2.3). Enhanced 23S rRNA fragmentation was also 
detected by Northern hybridization analysis for the RNase III, R and PH deficient strains after 
antibiotic treatment (Figure 2.4). A measurement of the fragment sizes was determined for both 
16S and 23S rRNA by G box Analysis (Figure 2.3 and Figure 2.4). These results substantiate the 
observations made by sucrose gradient and gel analysis of rRNA degradation.  
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Fig. 2.3 Northern hybridization analysis of 16S rRNA fragmentation for wild type and RNase 
mutant E. coli cells. RNA was isolated from cells grown as indicated with 10µg/mL 
aminoglycosides. RNA sequences were identified by hybridization with a 16S DNA probe and 
nucleotide sizes are indicated. Control (C), Neomycin (N), Paromomycin (P) 
 
 
470 
360 
240 
575 
300 
600 
450 
640 
780 
455 
489 
660 
380 
740 
150 
280 
400 
500 
56 
 
 
Fig. 2.4 Northern hybridization analysis of 23S rRNA fragmentation for wild type and RNase 
mutant E. coli cells. RNA was isolated from cells grown as indicated. RNA was isolated from 
cells grown as indicated with 10µg/mL aminoglycosides. RNA sequences were identified by 
hybridization with a 23S DNA probe and nucleotide sizes are indicated.  Control (C), Neomycin 
(N), Paromomycin (P) 
 
 
Discussion 
 Aminoglycosides are a widely used family of antibiotics that target the bacterial ribosome 
(Sutcliffe 2005). They bind to both subunits of the ribosome and affect both translational 
accuracy and ribosomal subunit recycling. Neomycin and paromomycin are structurally similar 
compounds and interact with the subunit rRNAs in similar ways.  Both antibiotics stall the 
assembly of the 30S subunit in addition to impairing translation (Champney 2006).  
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 Ribonucleases function in rRNA processing and degradation (Deutscher 2009). RNases III, 
E, G, and PH are involved in the processing of precursor rRNA during subunit synthesis. RNase 
III is responsible for the initial cleavage of the precursor rRNA (Deutscher 2009). RNase G and 
E function in processing of the 5’ end of 16S rRNA (Li et al. 1999). Additionally, RNase G and 
PH are involved in processing of 23S rRNA (Song et al. 2011; Gutgsell and Jain 2012).  RNase 
III, RNase E, and RNase PH are also involved in rRNA degradation in addition to RNase II, R, 
and PNPase (Deutscher 2009; Arraiano et al. 2010). RNase E, PNPase, enolase, and the DEAD-
box helicase Rh1B form a complex known as the degradosome. The degradosome is responsible 
for degradation of rRNA under some circumstances (Vanzo et al. 1998). RNase R initiates rRNA 
degradation by binding to a 3’ terminus overhang (Vincent and Deutscher 2006). 
 Elimination of specific RNases by mutation is predicted to enhance the effectiveness of 
antibiotics which stall ribosomal subunit formation by reducing the ability to recycle ribosomal 
subunits.  E. coli cells with a mutation in RNase E showed enhanced sensitivity to erythromycin 
and the accumulation of a precursor to the 50S subunit (Usary and Champney 2001). E. coli cells 
deficient for RNase II or PNPase showed an enhanced sensitivity to azithromycin and an 
impairment of 23S rRNA function. Turnover of the RNA was stimulated and 50S ribosomal 
subunit formation was impaired by azithromycin treatment. In addition, recovery of subunit 
formation after antibiotic removal was impaired (Silvers and Champney 2005). Based on these 
findings, it was hypothesized that E. coli cells deficient for specific RNases would display an 
increased sensitivity to aminoglycosides. 
 The enzymes identified in this study to affect sensitivity to aminoglycosides are, for the 
most part, different from the enzymes shown to affect erythromycin and azithromycin sensitivity 
(RNase E and RNase II and PNPase). The difference in RNases in the two cases may result from 
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the differences in the effects of macrolides and aminoglycosides on the subunit assembly 
sequence. In this study, E. coli deficient for RNases III, E, R, G, or PH displayed an increased 
sensitivity to neomycin or paromomycin. Aminoglycosides affect both 30S and 50S ribosomal 
subunit synthesis while macrolides only affect 50S ribosomal subunit assembly (Champney and 
Tober 2000; Usary and Champney 2001; Mehta and Champney 2002). During transcription, 16S 
rRNA is transcribed first and initiates 30S precursor assembly prior to 23S and 5S rRNA 
synthesis for 50S precursor formation.  Aminoglycoside antibiotic stalling of 30S formation 
leads to the accumulation of a 21S precursor, whose rRNA will not be further processed in 
specific RNase deficient mutants. Macrolide antibiotic stalling of 50S assembly generates a 32S 
precursor to the 50S particle which would need to be removed by the rRNA degradative enzymes 
RNase II and PNPase as observed (Silvers and Champney 2005).  
 The somewhat larger effects of the aminoglycosides on subunit synthesis and rRNA 
degradation in strain SK5729 may be due to additional RNase mutations in this strain. The strain 
lacks RNases I, II, PH and PNPase. However, examination of a mutant strain (N7060) deficient 
for RNase I, II, and PNPase showed no significant effects on subunit synthesis or rRNA 
degradation in the presence of either aminoglycoside (A. F. unpublished).  We would conclude 
that the aminoglycoside effects in SK5729 are therefore likely due to the loss of RNase PH and 
not to the lack of the other ribonucleases. 
 In summary, this research has identified rRNA processing RNases as important in the 
effectiveness of aminoglycoside antibiotic inhibitory activity. Inhibition of processing RNases by 
small molecule inhibitors or RNA interference methods could represent an attractive new 
antimicrobial target. 
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ABSTRACT 
The increase in antibiotic resistant microorganisms has driven a search for new antibiotic 
targets and novel antimicrobial agents. A large number of different antibiotics target 
bacterial ribosomal subunit formation. Several specific ribonucleases are important in the 
processing of rRNA during subunit biogenesis.  This work demonstrates that the 
ribonuclease inhibitor, vanadyl ribonucleoside complex (VRC), can inhibit RNases 
involved in ribosomal subunit formation. The ribosomal subunit synthesis rate was 
significantly decreased and ribosomal RNA from the subunit precursors was degraded. 
VRC had no inhibitory effect on translation. VRC also enhanced the inhibitory effects of 
an aminoglycoside and a macrolide antibiotic.  
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INTRODUCTION 
The increase in antibiotic resistance is a global threat to both physicians and scientists (30). An 
important area of investigation is to discover novel antimicrobial agents to which resistance has 
not yet been developed.  In addition, a significant effort is being made to identify new cellular 
targets for drug discovery (1, 4, 19). 
 The bacterial ribosome is a target for a diverse collection of different antibiotics (9, 36). 
Drug binding sites and molecular mechanisms of action have been described recently for many 
of these compounds based on refined crystal structures (7, 9, 14, 15, 25, 34). Most of these 
antibiotics bind to the 30S or 50S ribosomal subunit and inhibit translation of mRNA. 
Importantly, biogenesis of the subunits is an additional cellular target for many of these agents 
(8). When synthesis of either subunit is inhibited, specific ribonucleases (RNases) proceed to 
degrade the rRNA in the ribosomal subunit assembly intermediates (9). In particular, RNase E is 
important in the turnover of a 50S subunit precursor particle present in erythromycin-inhibited 
cells (34) and the enzymes RNase II and PNPase are also involved in rRNA degradation in cells 
inhibited by azithromycin (31). 
 In Escherichia coli cells, at least five different RNases are needed to generate and process 
the 5’ and 3’ ends of 16S, 23S and 5S rRNA (18, 23, 32, 35). Subunit assembly intermediates are 
the substrates for these activities. Mutant organisms missing any of these proteins show an 
enhanced sensitivity to both paromomycin and neomycin (16). These observations suggest that 
RNases in E. coli cells could be novel targets for antimicrobial agents. Inhibition of certain 
RNases is predicted to enhance the inhibitory effects of antibiotics targeting subunit formation 
(31, 34). 
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The vanadyl ribonucleoside complex (VRC) is a low molecular weight inhibitor of 
RNases that is commonly used during the isolation of RNA from cells (2, 28, 29).  Although its 
target specificity is unknown, the compound is thought to target endoribonucleases (2). VRC has 
been shown to reduce the synthesis of both ribosomal subunits in Staphylococcus aureus (17). 
Cell viability was reduced in this organism and rRNA degradation was stimulated. The 
compound also enhanced the inhibitory effects of both paromomycin and azithromycin. 
We hypothesized that VRC could therefore function as a novel antimicrobial agent in a 
gram negative organism, like E. coli. This work shows that VRC caused an inhibitory effect on 
ribosomal subunit formation in E. coli cells without affecting bacterial protein synthesis rates. 
VRC also enhanced the growth inhibitory effects of paromomycin and azithromycin in these 
cells. This work indicates that inhibition of RNases is a new drug target. 
 
MATERIALS AND METHODS 
Cellular growth and viability.  Escherichia coli strain SK901 (22) cells were grown in a 37
o
C 
water bath in tryptic soy broth (TSB). After 10 minutes of initial bacterial growth, 5mM vanadyl 
ribonucleoside complex (VRC, New England Biolabs) was added to the cells. Paromomycin or 
azithromycin were added to some cultures at concentrations of 5µg/mL or 10µg/mL. The cells 
were grown for two cellular doublings to approximately 4x10
8
 colony forming units (CFU)/mL. 
VRC caused a color change to the TSB media used here which made an estimate of the growth 
rate by turbidity changes difficult. Growth rates were measured as an increase in cell number 
with time after serial dilution and plating on TSB agar plates as previously described (20).  
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Rate of protein synthesis.  Bacterial cultures were grown as above in the presence or absence of 
0.5, 1, or 5mM VRC. After two cellular doublings, 1µCi/mL of 
35
S-methionine (1175 Ci/mmol, 
MP Biomedicals) was added. Following the addition of the
 
radioisotope, three 0.2mL samples 
were removed at 5 min intervals. Samples were precipitated in 10% TCA with 100µg of BSA, 
collected and washed on Whatman GF/A glass fiber filters. The filters were placed into vials 
containing 3mL Scintisafe gel. Radioactivity was measured by liquid scintillation counting.  
Ribosomal subunit assembly. Cells were grown as described above. Following the addition of 
5mM VRC at a Klett of 20, paromomycin, or azithromycin were added to the appropriate 
cultures. After 15 minutes of growth with the antibiotics, 
3
H-uridine at 1µCi/mL (30 Ci/mmol, 
Am. Radiochemicals) and uridine at 2µg/mL were added. After the cells had grown through two 
doublings, 50µg/mL of uridine was added and the cells were incubated an additional 15 min. 
Cells were collected by centrifugation and were stored frozen at -70°C.   
 Cellular lysates were prepared by a lysozyme-freeze thaw method as previously described  
(14). The lysates were centrifuged through 5-20% sucrose gradients in S buffer in an SW 41 
rotor at 187813  x g for 3.5 hours (31). Following centrifugation fractions were collected after 
pumping through an ISCO Model UA-5 absorbance monitor set at 254nm. The fractions were 
collected into vials and mixed with 3mL Scintisafe gel before measuring the radioactivity by 
liquid scintillation counting. 
Uridine pulse and chase labeling. Cell cultures of 12ml were grown to a Klett of 20 and then 
5mM VRC was added.  Following one cellular doubling, the cells were pulse labeled with 
3
H-
uridine (1µCi/ml) for 90 sec and then chased with uridine at a concentration of 25µg/ml. At six 
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time intervals, 2ml samples were removed, collected by centrifugation, and stored frozen before 
analysis by sucrose gradient centrifugation as previously described (12, 31). 
Agilent Bioanalysis of RNA. Bacterial cells were grown as described above. At a density of 
4x10
8
 cells/mL, the cells were collected by centrifugation and RNA was extracted from the cell 
pellet using a chloroform/phenol extraction procedure as detailed by a published method (29). 
Total RNA was examined using an Agilent Bioanalyzer 2100 and the RNA 6000 chip. The 
sample preparation, loading procedure and run was carried out according to manufacturer’s 
instructions for total RNA analysis. Generally 0.5 to 1µg of RNA was examined. 
Northern blot hybridization. Biotinylated 16S and 23S specific probes were constructed by 
PCR as previously described (31).  The 16S (241 bp) and 23S (146 bp) DNA probes were 
amplified from plasmid pKK3535 DNA (3) using the polymerase chain reaction with primers 
from Life Technologies. The 23S primers used were (23S F) TAG GGG AGC GTT CTG TAA 
G and (23S R) CCC ATT AAC GTT GGA C (nt. nos. 1188-1334). The 16S primers used were 
(16S F) GGA GGA AGG TGG GGA TGA CG and (16S R) ATG GTG ACG GGC GGT GTG 
(nt. nos. 1173-1414). PCR products were purified by extraction with phenol and chloroform and 
precipitation with 2 volumes of ethanol. The pellets were resuspended in 30µL of sterile water. 
The purified DNA probes were labeled with biotin using the Label-IT biotin labeling kit (Mirus) 
(31). 
 Six micrograms of total RNA was denatured by heating at 55
o
C for 10 minutes and 
separated on a 5% TAE PAGE gel as previously described (29). RNA was transferred from the 
gel onto Nytran nylon membranes using a Turbo blot apparatus (S&S).  The membranes were 
pre-hybridized in 15mL of 1X pre-hybridization solution at 42
o
C for 30 minutes. The membranes 
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were then hybridized overnight at 42
o
C with 6mL hybridization buffer, 1X background 
quencher, and 4pmol of the denatured 16S or 23S specific probe as previously described (31).  
 After hybridization, the membranes were washed and the probe detected via the 
North2South chemiluminescent hybridization kit (Pierce Chemical Co.) with strepavidin-
conjugated horseradish peroxidase. Quantitative analysis of the rRNA fragmentation was 
determined by the G Box image analysis system (SynGene).  
Statistical analysis. Statistics differences were determined by Student t-test. Each antibiotic or 
VRC sample was compared to the control cells without VRC or antibiotics. In each table, an 
asterisk indicates a statistical significance on P<0.05.  
 
RESULTS 
 We have shown previously that 5mM VRC reduced the viability of S. aureus cells by over 
90% and the compound also enhanced the effectiveness of two antibiotics in this microorganism 
(17).  The effects of VRC and the same antibiotics on growth of E. coli cells were determined by 
colony counting of cell samples. E. coli cells grown with 5mM VRC alone showed a decrease in 
the viable cell counts or CFU (Table 3.1). Azithromycin alone led to an approximate 60% 
reduction in CFU; however, the inhibitory activities of azithromycin were enhanced in the 
presence of 5mM VRC. This inhibition was seen as an additive effect of the VRC. Paromomycin 
alone showed a significant decrease in the viable cell numbers, while the addition of VRC and 
paromomycin led to an increase in cell numbers comparable to the control cells without 
antibiotics or VRC (Table 3.1).  
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TABLE 3.1 VRC effects on cellular antibiotic sensitivity 
 
 CFU (x10
7
/mL) 
Control           101±11.2 
Paromomycin              8±1.0 (7.9) *   
Azithromycin          40±5.2 (39.6) * 
Control + VRC       87±7.9 (86.1) 
Paromomycin + VRC 126±10.2 (124.8) 
Azithromycin + VRC           18±2.4 (17.8) *        
The percentage reduction in viability compared with the control cells for each strain is listed in 
parenthesis. Antibiotics were used at 5µg/mL. Results are the means ± standard error of 3 
independent experiments. (*) statistically significant with a P value <0.05 
 
 
 Based on the prior work in S. aureus (17), we tested whether the addition of VRC would 
lead to a decrease in ribosomal subunit amounts in E. coli cells.  The distribution of 
3
H-uridine 
labeled rRNA after sucrose gradient centrifugation was used to examine 30S and 50S subunit 
levels (Fig. 3.1a). Substantial reductions in the amounts of both particles were seen (Table 3.2). 
The addition of 5mM VRC led to a 26% reduction in 30S and a 45% reduction in 50S subunit 
levels (Table 3.2). In addition, a 26% increase in radio-labeled RNA was seen in the top gradient 
fractions, indicative of rRNA degradation (31). The increase was proportional to the loss of 
rRNA from both subunits (24%).  
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FIG 3.1 Sucrose gradient profiles of 
3
H uridine labeled ribosomal subunits. Gradient profile for 
subunits from cells grown without and with VRC (a). Gradient profile for subunits from cells 
grown with VRC and 5µg/mL paromomycin (b). Gradient profile for subunits from cells grown 
with VRC and 5µg/mL azithromycin (c). Note the differences in the left (without VRC) and right 
(with VRC) axis.  
 
 
TABLE 3.2 Distribution of ribosomal subunits in sucrose gradient regions 
 
 % Total gradient radioactivity 
Treatment Top gradient region 30S region  50S region  
Control  29.09±2.6 23.83±0.7  41.19±2.5 
Paromomycin     38.34±4.3 (131.8)    32.12±7.1 (134.8) *       24.92±3.7 (60.5) * 
Azithromycin     42.45±7.6 (145.9)    30.74±4.1 (129.0) *       22.27±3.5 (54.1) * 
Control + VRC        55.99±2.2 (192.5) *      17.84±1.5 (74.9) *       22.66±1.6 (55.0) * 
Paromomycin + VRC        71.33±2.6 (245.2) *      12.29±2.6 (51.6) *       13.89±2.4 (33.7) * 
Azithromycin + VRC        61.90±1.8 (212.8) *   23.4±1.40 (98.2)        10.05±0.3 (24.4) * 
Cells were grown in the presence of 5µg/mL paromomycin or azithromycin and 5mM VRC. 
Radioactivity in gradient fractions corresponding to the top, 30S, and 50S regions was summed 
and calculated as a percent of the total radioactivity in the gradient. Percentage of the differences 
in the 30S and 50S regions in comparison to the control is shown.  Results are the means ± 
standard error of 2 independent experiments. (*) statistically significant with a P value <0.05 
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 When 5µg/mL of paromomycin or azithromycin was added to the bacterial cells, 30S and 
50S subunit assembly was impaired (Fig. 3.1; Table 3.2).  Degradation of rRNA was stimulated 
by both compounds (Fig. 3.1b, 3.1c). The addition of VRC in combination with the antibiotics 
led to a further reduction in 30S and 50S subunit amounts and an enhancement in rRNA 
degradation (Table 3.2). For example, when E. coli cells were incubated with 5µg/mL 
azithromycin there was a 129% increase in the 30S subunit assembly, a 46% reduction in the 50S 
subunit assembly and a 146% increase in the top of the gradient radio-labeled RNA. The increase 
in 30S subunit assembly could be attributed to an increase in the 50S precursor, 32S. When the 
E. coli cells were also incubated with 5mM VRC, there was a 2% reduction in 30S subunit 
assembly, a 76% reduction in 50S subunit assembly, and a 213% increase in the top of the 
gradient radio-labeled RNA compared to that of the untreated control cells. The proportional 
increase in RNA degradation was seen in each instance (Table 3.2). Table 3.3 shows the net 
reduction in the amounts of both subunits resulting from VRC inhibition alone and in 
combination with each antibiotic. 
 
TABLE 3.3 Inhibition of subunit synthesis by VRC and antibiotics 
 
 % Control amount 
Treatment 30S  50S  
Control 100.0±13.3 100.0±14.6 
Control + VRC    43.1± 8.1 * 31.4±5.5 * 
Paromomycin + VRC   18.6±14.3 *   6.0±2.7 * 
Azithromycin + VRC   47.3±15.5 * 11.1±3.5 * 
Cells were grown in the presence of 5µg/mL paromomycin or azithromycin and 5mM VRC. 
Total radioactivity in the 30S or 50S subunit regions of the VRC treated samples was compared 
with radioactivity in the same gradient region of control cells. Percentage of the total 30S and 
50S subunits in comparison to the control is shown.  Results are the means ± standard error of 3 
independent experiments. (*) statistically significant with a P value <0.05 
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 The effect of VRC on subunit synthesis rates was measured by a 
3
H-uridine pulse and chase 
labeling procedure. Figure 3.2 shows that the rates of 30S (Fig. 3.2a) and 50S (Fig. 3.2b) subunit 
formation in the absence of VRC. Assembly was complete in 60 min at 27°C (Figure 3.2).  
Growth with 5mM VRC lengthened the time for the rate of subunit assembly by about 24-fold, 
with 50% of net subunit formation completed in 120 min. 
 
 
FIG 3.2 Subunit synthesis rates from 
3
H uridine pulse-chase labeling assays. (a) Rates of 
formation of 30S subunits in cells growing with or without 5mM VRC. (b) Rates of formation of 
50S subunits in cells growing with or without 5mM VRC. Results are the means ± standard error 
of 2 independent experiments.  
 
 
 Antibiotics which inhibit ribosomal subunit formation also affect translation (33). Protein 
synthesis rates in bacterial cells were measured in the presence of several concentrations of VRC 
to examine its effect on translation. The data in Figure 3.3 demonstrate that the rate of protein 
synthesis was increased slightly with increasing VRC concentrations but no inhibitory effects 
were seen. Combined with the decrease in 30S and 50S subunits, the protein synthesis results 
indicate that VRC affects the assembly of ribosomal subunits without affecting either subunit’s 
function and further indicates that VRC inhibits rRNA processing ribonucleases. 
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FIG 3.3 Protein synthesis rates for cells growing without and with VRC.  Results are the 
means ± standard error of 2 independent experiments. 
 
 
 The effect of VRC and the two antibiotics on rRNA turnover was examined in more detail.  
The Agilent chip methodology was used to examine rRNA status in all cells. Figure 3.4 shows 
the gel pattern and Table 3.4 gives a quantitative analysis of the rRNA distribution. The amounts 
of both 16S and 23S rRNAs in E. coli were reduced by each experimental treatment compared to 
those in untreated control samples (Table 3.4). The treatment of antibiotics alone increased 
rRNA while decreasing 16S and 23S rRNA. VRC alone reduced the 16S and 23S rRNA 
amounts, and increased the RNA degradation observed when either antibiotic was added. Bands 
the approximate size of the precursor forms of 16S rRNA were apparent in each case where 
antibiotics were added and appeared to show more accumulation when VRC and antibiotics were 
present. The band representing the 16S precursor can be seen directly above the 16S rRNA band 
in the Agilent gel (Table 3.4).  
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FIG 3.4 Agilent gel analysis of total RNA. RNA samples were analyzed by the Agilent 
Bioanalyzer. (a) RNA isolated from cells grown in the presence of 5µg/mL antibiotics. Lane 1, 
control cells;  lane 2, cells grown with paromomycin; lane 3, cells grown with azithromycin;  
lane 4, cells grown with 5mM VRC; lane 5, cells grown with paromomycin and 5mM VRC; lane 
6, cells grown with azithromycin and 5mM VRC. (b) RNA isolated from cells grown in the 
presence of 10µg/mL antibiotics. Lanes are as in (a) 
 
 
TABLE 3.4 The amount and distribution of 23S, 16S, and small RNA species as determined by 
Agilent gel electrophoresis analysis 
 
 % Total area 
Treatment RIN Small RNA 16S rRNA 23S rRNA 
Control 9.2±0.7 22.63±13.1 31.47±4.5 43.73±5.7 
Paromomycin    6.5±0.1 (71.2) 23.30±2.3 (103.0)   15.35±0.2 (48.8)      13.05±0.2 (29.8) * 
Azithromycin       6.1±0.1 (65.8) * 27.25±3.7 (120.4)   15.10±0.1 (48.0)        7.10±0.1 (16.2) * 
Control + VRC 9.6 ±0.5 (104.3)   13.53±3.0 (59.8)   24.57±2.6 (78.1) 35.93±10.1 (82.2) 
Paromomycin + VRC       5.7±0.1 (62.0) * 38.55±0.2 (170.3)      12.00±0.1 (38.1) *        6.35±0.1 (14.5) * 
Azithromycin + VRC       5.6±0.1 (60.9) * 38.90±2.3 (171.9)        8.65±0.2 (27.5) *        4.50±0.1 (10.3) * 
Cells were grown in the presence of 10µg/mL paromomycin or azithromycin and 5mM VRC. 
RNA in each gel region from Figure 3.4 was computed by analysis of the electropherograms 
using Agilent software.  Percentage of the total RNA in comparison to the control in each gel 
region is shown. The RNA integrity number (RIN) is indicated. Results are the means ± standard 
error of 2 independent experiments. (*) statistically significant with a P value <0.05 
 
 
a b 
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 Northern hybridization analysis was used to examine the rRNA fragmentation with more 
specificity. Probes specific for 16S and 23S rRNA sequences were used to test for the 
degradation of each type of rRNA. The gel pattern is shown in Figure 3.5, and shows that equal 
amounts of RNA were loaded onto the gel. The probe hybridization results are shown in Figure 
3.6, and indicate that VRC alone produced some fragmentation of 16S (Figure 3.6a).  Each 
antibiotic stimulated 16S rRNA fragmentation as shown previously (15). However, when VRC 
and the antibiotics were used together, the fragmentation of both rRNA species was enhanced 
and there was an increase in the smaller RNA fragments (Fig. 3.6). The addition of VRC in 
combination with VRC led to an increase in 23S rRNA fragmentation (Figure 3.6b). These 
results confirm the degradation of rRNAs indicated by the gradient centrifugation and Agilent 
gel results.  
 
FIG 3.5 Analysis of rRNA fragmentation by gel electrophoresis.  RNA samples are: lane 1, 
control cells; lane 2, cells grown with 10µg/mL paromomycin; lane 3, cells grown with 10µg/mL 
azithromycin;  lane 4, cells grown with 5 mM VRC; lane 5, cells grown with 10µg/mL 
paromomycin and VRC; lane 6, cells grown with 10µg/mL azithromycin and VRC. 
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FIG 3.6 Northern hybridization analysis of rRNA fragmentation. RNA was isolated from cells 
grown in the presence of 10µg/mL antibiotics and/or 5mM VRC. (a) 16S rRNA hybridization. 
The samples are lane 1, control cells; lane 2, cells grown with paromomycin; lane 3, cells grown 
with azithromycin;  lane 4, cells grown with 5 mM VRC; lane 5, cells grown with paromomycin 
and VRC; lane 6, cells grown with azithromycin and VRC. (b) 23S rRNA hybridization. Lanes 
as in (a). Position of estimated sizes of the rRNA fragments are indicated. 
 
 
a 
b 
520 
470 
510 
470 
511 
450 
385 
280 
350 
422 
475 
250 
350 
417 
473 
131 
316 
174 
163 
286 
366 
495 
617 
275 
360 
460 
861 
77 
 
DISCUSSION 
  Bacterial ribosomes are essential structures in all prokaryotic cells. Expression of genetic 
information relies on accurate and rapid translation of mRNA sequences.  A very large number 
of antimicrobial agents target the translation process causing either bacterial stasis or 
bacteriocidal effects (9, 24).  Ribosomal subunit formation is an essential process for bacterial 
cell growth and viability and is also a target for many of these same translational inhibitors (9). 
 The present work builds on several of our previous findings regarding various aspects of 
antibiotic inhibition of bacterial ribosome formation (6, 8, 13, 15, 25, 26, 34).  A large number of 
different translational inhibitors can stall ribosomal subunit formation in growing cells (10-12). 
Mutant strains of E. coli deficient in specific RNases showed an enhanced sensitivity to both 
macrolide (31, 34) and aminoglycoside (16) antibiotics, and subunit formation was impaired in 
each case while rRNA degradation was stimulated. In addition, treatment of S. aureus with an 
inhibitor of RNases, VRC,  promoted similar effects, slowing subunit formation and enhancing 
rRNA turnover (17). The present work extends the evidence showing that impairment of subunit 
formation by mutation or small molecule inhibitors is detrimental to cell growth. It is 
hypothesized that the increase in viable cells when paromomycin and VRC are present is due to 
an effect on messenger RNA turnover (21, 27). This is because VRC is efficient at decreasing 
ribonucleases and ribonucleases have been shown to be important in mRNA turnover (2, 5). One 
surprising observation was increased viability of E. coli cells treated with paromomycin and 
VRC (Table 3.1). At this time, we have no explanation for the increase in cell viability in these 
cells since they have also been shown to have a significant decrease in subunit assembly and an 
increase in 16S and 23S rRNA fragmentation.  
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 The specific ribonuclease(s) inhibited by VRC in these cells are unknown. RNase III is one 
likely target since the formation of both subunits was impaired to the same extent. This enzyme 
generates both precursor 16S and 23S rRNAs from the primary transcript (37) and is a 
endoribonuclease, the likely substrate for VRC (2). Other processing endo-RNases like RNase E, 
G, R or PH could also be affected by VRC (16). VRC may certainly have other effects on tRNA 
or mRNA metabolism in cells in addition to the inhibitory effect on subunit formation. These 
remain to be investigated. 
 A separation of the inhibition of subunit formation and subunit function in translation is a 
finding from this research. A large reduction in the rate of synthesis of both subunits was 
revealed without a concomitant reduction in translation rates. Preexisting ribosomes in VRC 
treated cells seem capable of normal rates of protein synthesis. This data further indicates that 
VRC is reducing the rate of ribosomal subunit formation without affecting the function of the 
bacterial ribosome. Due to the lack of inhibition of translation (Figure 3.3) the effects of VRC 
are more than likely due to assembly inhibition and not an effect on translation.  
 The results described here can be interpreted as follows. Either of the two antibiotics is 
capable of binding to a subunit precursor particle and stalling subunit maturation, as we have 
previously demonstrated (15, 25). VRC alone likely impairs the processing of rRNA precursor 
sequences, a process essential for subunit maturation as well (17). Combining VRC with an 
antibiotic will generate a stalled subunit precursor in a cell with a reduced rRNA processing 
capability, thus enhancing the effectiveness of the antimicrobial agent. 
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 Inhibition of rRNA processing RNases indicates a new antimicrobial target in cells.  A 
search for other small molecule inhibitors of RNase activity or the application of current RNA 
interference methods may promote the development of more effective current or novel 
antimicrobial therapies. 
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ABSTRACT 
Objectives: The discovery of new antibiotic targets is important to stem the increase in antibiotic 
resistance against most currently used antimicrobials.  The bacterial ribosome is a major target 
for a large number of antibiotics which inhibit different aspects of translation. Some of these 
antimicrobial agents also inhibit ribosomal subunit formation as a second cellular target. Precise 
subunit assembly requires the activity of several distinct RNases for proper rRNA processing. 
The present work shows that the vanadyl ribonucleoside complex (VRC) inhibited RNases 
involved in ribosomal subunit formation without an effect on translation. 
 
Materials and methods: Methicillin sensitive and methicillin resistant strains of Staphylococcus 
aureus were examined for the inhibitory effects of VRC on cell viability by colony counting. 
Protein synthesis rates were measured by isotopic methionine incorporation. Ribosome synthesis 
was measured by isotopic uridine incorporation into ribosomal subunits as displayed on sucrose 
gradients. Pulse and chase radiolabeling was used to measure subunit synthesis rates. RNA 
turnover was determined by Agilent assay. 
 
Results: The rates and amounts of subunit synthesis were significantly reduced in the presence 
of the compound. Ribosomal RNA was degraded and cell viability was reduced as a 
consequence. VRC also enhanced the inhibitory effects of macrolide and aminoglycoside 
antibiotics on ribosome formation. 
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Conclusions: Bacterial ribosomal subunit synthesis was specifically impaired in VRC treated 
cells with the rates and amounts of both subunits reduced. Cell viability was significantly 
reduced and rRNA turnover was stimulated. 
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Introduction 
Antibiotics play an important role in global health. However, antibiotic resistance is becoming an 
increasing problem world-wide 
1
. The discovery of novel drug targets and new types of 
antimicrobial agents is necessary to control infections caused by resistant microorganisms 
2
. 
A major cellular target for various, currently used antimicrobial agents is the bacterial 
ribosome.  Many steps in the complex process of translation can be inhibited by different 
compounds. Information on the specific inhibitory effects of many translational inhibitors has 
been reviewed recently 
3
. The biogenesis of the large and small ribosomal subunit in bacteria is a 
second target for many of these same antibiotics 
4
. 
Bacterial ribosomal subunit assembly begins with specific ribosomal proteins adding to 
the nascent 16S, 23S, and 5S ribosomal RNA transcripts. For both 30S and 50S synthesis, an 
intermediate precursor particle is formed initially. These particles contain a subset of the total 
ribosomal proteins found in the mature subunit and precursor forms of the 16S and 23S rRNA 
5
.  
Endo- and exonucleolytic cleavage of the precursor rRNAs by ribonucleases is essential for 
generation of the mature subunits 
6
. Mutant strains of E. coli deficient in specific RNases are 
hypersensitive to azithromycin 
7
 and to aminoglycoside antibiotics (A. F., unpublished). 
Maturation of the precursors into mature subunits is delayed in these mutants and an increase in 
the degradation of rRNA can be observed 
7
. Antibiotics targeting subunit assembly inhibition has 
been investigated 
8
; however, the use of RNase inhibition to potentiate the effects of currently 
used antibiotics has not been examined.  
The vanadyl ribonucleoside complex (VRC) is a low molecular weight inhibitor of 
RNases that has been used during the isolation of RNA from cells 
9-11
.  It is an effective inhibitor 
of cellular RNases although its target specificity is unknown. We reasoned that VRC could target 
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and inhibit RNases involved in ribosomal subunit assembly and thus function as a novel 
antimicrobial agent. This work shows that VRC can specifically inhibit ribosomal subunit 
formation in both methicillin sensitive (MSSA) and methicillin resistant (MRSA) S. aureus cells 
without an inhibitory effect on protein synthesis. VRC was found to enhance the inhibitory 
effects of paromomycin and azithromycin in these organisms. The results indicate that RNases 
may be a novel antibiotic target. 
 
 
Material and Methods 
Cellular growth and viability 
Methicillin sensitive Staphylococcus aureus RN1786 
12
 and the methicillin resistant strain A1024 
13
 were grown at 37
o
C in tryptic soy broth (TSB). After one hour of initial bacterial growth, 
5mM VRC (New England BioLabs) was added to the cells. For some experiments, paromomycin 
or azithromycin were added at a concentration of 1.5µg/mL or 5µg/mL respectively. Growth 
rates were measured as an increase in cellular density over time using a Klett-Summerson 
colorimeter as previously described 
14
. Cellular viability was determined by colony counting on 
TSB agar plates after serial dilution as described 
15
.  
Protein synthesis assay 
Cells were grown as described above in the presence or absence of 5mM VRC. After two 
cellular doublings, 1µCi/mL of 
35
S-methionine (1175 Ci/mmol, MP Biomedicals) was added. 
Following the addition of the isotope, three 0.2mL samples were removed at 5 minute intervals. 
Each sample was precipitated in 10% TCA with 100µg/ml of BSA, collected and washed on 
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Whatman GF/A glass fiber filters. The filters were placed into vials containing 3mL Scintisafe 
gel. 
35
S- Methionine radioactivity was measured by liquid scintillation counting. 
Uridine pulse and chase labeling 
Two 12ml cultures of cells, one control and one with VRC at 5mM were grown to a Klett of 40. 
The cells were pulse labeled with 1µCi/ml 
3
H-uridine (30 Ci/mmol, Am. Radiochemicals) for 90 
sec and then chased with uridine at 25µg/ml. At intervals, 2ml samples were removed, collected 
by centrifugation, washed and stored frozen before lysis for sucrose gradient centrifugation as 
described 
7, 16
. 
Ribosomal subunit assembly  
 Bacterial cell cultures were grown in TSB as described. Following the addition of VRC at a 
Klett of 20, paromomycin or azithromycin was added to the appropriate culture. After 15 
minutes of growth with the antibiotics, 
3
H uridine at a concentration of 1µCi/mL and uridine at a 
concentration of 2µg/mL were added. The cells were allowed to grow for two cellular doublings. 
At that time, uridine was added to 50µg/mL and the cells were incubated an additional 15 
minutes. Cells were collected by centrifugation and stored frozen at -70
o
C.  
 Cellular lysates were prepared with lysostaphin, DNase I and Trition X100 as previously 
described 
16
. The samples were centrifuged through 5-20% sucrose gradients in S buffer in an 
SW41 rotor at 187813 x g for 3.5 hours 
7
. Following centrifugation, sample fractions were 
collected by pumping them through an ISCO Model UA-5 absorbance monitor set at 254nm. The 
fractions were collected into vials and mixed with 3mL Scintisafe gel before measuring the 
3
H 
uridine by liquid scintillation counting. 
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Agilent bioanalysis of RNA 
 Bacterial cells were grown as previously described above. At a density of 4x10
8
 cells/mL, the 
cells were collected by centrifugation and RNA was extracted from the cell pellet. Total RNA 
was isolated by a spin column procedure with the RNA isolation kit from Norgen (Norgen 
Biotek Corp).  RNA was examined using an Agilent Bioanalyzer 2100 and the RNA 6000 chip. 
Typically 0.5 to 1µg of RNA was analyzed via chip analysis conducted according to the 
manufacturer’s instructions for total RNA analysis.  
Eukaryotic cell growth 
Growth of eukaryotic cells in tissue culture was performed as follows: 20,000 macrophage 
(RAW 264.7 cells; 
17
) or 10,000 fibroblast cells (BJ cells; ATCC) were seeded into a 96-well 
plates with 200µL supplemented RPMI 1640 or DMEM media respectively. Both macrophage 
and fibroblasts were grown at 37
o
C in a 5% CO2/95% air humidified atmosphere. After two or 
twelve hours of initial growth respectively, 0.5, 1, or 5mM VRC were added to the appropriate 
wells. After an additional two hours of growth for each cell type, 10µg/mL of paromomycin or 
azithromycin was added to the wells. The cells were allowed to grow for approximately 32 
additional hours before performing a Cell Titer 96® AQueous one solution cell proliferation 
assay as per manufacturer’s instructions (Promega).  
Statistical analysis 
 Statistical differences were determined by Student t-test. Each antibiotic or VRC sample was 
compared to the control cells without VRC or antibiotics. In each table, an asterisk indicates a 
statistical significance of P<0.05.  
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Results  
The VRC was initially tested to see if it had an inhibitory effect on cell growth and viability. In 
both methicillin sensitive and methicillin resistant S. aureus cells, the addition of VRC decreased 
cell viability (Table 4.1).  When 5mM VRC was used, cell numbers were decreased by over 90% 
in both strains.  The addition of paromomycin alone led to a 92% and 18% reduction in cell 
viability for MSSA and MRSA cells respectively, while azithromycin led to a 92% and 95% 
decrease. VRC also enhanced the inhibitory effects of paromomycin and azithromycin on cell 
viability. The addition of VRC led to an increase in the efficiency of the antibiotics as seen by a 
statistically significant decrease in total viable cell counts compared with the effects of the 
antibiotics alone (Table 4.1).  
 
Table 4.1.  Effect of VRC and antibiotics on cell viability of S. aureus cells 
 
Strain Inhibitor Cell viability (x10
7/mL) 
Methicillin sensitive S. aureus (MSSA) none        209±66.7 
MSSA paromomycin           17±16.5 (8.1) * 
MSSA azithromycin             16±5.4 (7.7) * 
MSSA VRC             11±5.4 (5.3) * 
MSSA paromomycin + VRC               8±7.8 (3.8) * 
MSSA azithromycin + VRC             2±0.4 (0.96) * 
Methicillin resistant S. aureus (MRSA) none       306±85.9 
MRSA paromomycin  252±15.5 (82.4) 
MRSA azithromycin           17±6.2 (5.5) * 
MRSA VRC             5±1.3 (1.6) * 
MRSA paromomycin + VRC           11±5.9 (3.6) * 
MRSA azithromycin + VRC           1±0.6 (0.32) * 
The percentage reduction in viability compared with the control cells for each strain is listed in 
parenthesis. Results are the means ± standard error of 5 independent experiments. (*) statistically 
significant with P<0.05 
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Ribonucleases are essential for both ribosomal subunit assembly and for turnover of 
mRNA after translation. The inhibitory effect of VRC on translation and subunit formation was 
examined separately.  The incorporation of 
35
S-methionine into total cellular proteins was 
examined in both strains in the absence and presence of VRC.  As Figure 4.1 shows, the addition 
of VRC led to a slight increase in protein synthesis rates in both methicillin sensitive (MSSA) 
and methicillin resistant (MRSA) S. aureus cells; however, no significant inhibitory effect on the 
rate of translation was observed. 
 
(              ) MSSA without VRC     (          ) MSSA with VRC        
(         ) MRSA without VRC    (          ) MRSA with VRC 
  
Figure 4.1. Protein synthesis rates for MSSA cells and MRSA cells grown without or with 
5mM VRC.  Results are the means ± standard error of 3 independent experiments. 
 
 
 
 Ribosomal subunit assembly was examined in both strains by 
3
H uridine labeling during 
growth in the absence and presence of 5mM VRC. The subunits were separated by sucrose 
density gradient centrifugation to show the distribution of 
3
H uridine into the ribosomal subunits.  
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Figure 4.2a and 4.2b show the sucrose gradient profiles for the labeled subunits. In both 
microorganisms there was an overall 90% reduction in the formation of both subunits in the 
VRC treated samples when compared with the control. The data showed a 15 to 25% increase in 
3
H uridine labeled RNA in the slowly sedimenting top gradient fractions (Figure 4.2; Table 4.2). 
This result is indicative of rRNA degradation 
7
.   
 
Without VRC (       )      With VRC (      ) 
 
Figure 4.2. Sucrose gradient profiles of 
3
H uridine labeled ribosomal subunits isolated from 
cells grown without or with 5mM VRC. (a) Gradient profile for MSSA cells. (b) Gradient 
profile for MRSA cells. Note the differences in the left (without VRC) and right (with VRC) 
axis.  
 
 
Table 4.2.  Distribution of 
3
H uridine labeled RNA in sucrose gradient regions 
  
Strain % Total gradient radioactivity
a
 
 Top  30S  50S  
Methicillin sensitive S. aureus Control 33.17±1.0 21.68±0.1 41.58±0.9 
Methicillin sensitive S. aureus + VRC 57.03±1.8 
(171.9) * 
14.65±0.8 
(67.6) * 
24.57±0.8 
(59.1) * 
Methicillin resistant S. aureus Control  30.72±1.5 17.47±2.2 47.88±0.7 
Methicillin resistant S. aureus  + VRC 44.67±1.6 
(145.4) * 
17.68±0.3 
(101.2) 
32.98±2.0 
(68.9) * 
a
 Radioactivity in gradient fractions corresponding to the top, 30S and 50S regions was 
calculated as a percent of the total radioactivity in the gradient. Results are the means ± 
standard error of 3 independent experiments. (*) statistically significant with a P value <0.05 
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The influence of VRC on the rate of ribosomal subunit formation was examined by a 
3
H 
uridine pulse and chase labeling procedure. The rates of subunit formation in the absence of the 
inhibitor were equivalent to those observed previously in S. aureus 
16, 18
 (Figure 4.3). Synthesis 
of both subunits was completed by 60 minutes at 27°C.  Compared with control cultures, VRC 
reduced the rate of formation of both subunits in these organisms. The 50S subunit assembly rate 
was lengthened 4-fold under these conditions (Figure 4.3).  
 
With VRC (             )     Without VRC (         ) 
 
Figure 4.3. Kinetics of ribosomal subunit formation in cells growing with and without 5mM 
VRC. (a) Rates of formation of 30S subunits in MSSA cells. (b) Formation of 50S subunits in 
MSSA cells. (c) Rates of formation of 30S subunits in MRSA cells. (d) Formation of 50S 
subunits in MRSA cells. Results are the means ± standard error of 2 independent experiments. 
 
 
The status of rRNA in control and VRC treated cells was examined by the Agilent 
Bioanalyzer analysis.  Significant decreases in the relative amounts of both16S and 23S rRNA 
were observed in VRC treated cells of both strains (Figure 4.4). Bands representing the 
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approximate size of the precursor forms of both rRNA species could be seen directly above the 
16S and 23S rRNA bands. Growth with both VRC and antibiotics led to an increase in 
fragmented rRNA in these cells (Table 4.3). In both strains, the addition of VRC alone led to a 
significant 2 to 3- fold increase in smaller RNA molecules. The addition of VRC and 
paromomycin or azithromycin also led to a significant increase in small RNA molecules in 
MRSA cells (Table 4.3). 
 
 
 
Figure 4.4. RNA samples analyzed by the Agilent Bioanalyzer. Total RNA was isolated from 
MSSA and MRSA cells grown without and with VRC and antibiotics. (a) Agilent chip analysis 
of RNA from MSSA cells.  The RNA samples are: lane 1, control cells; lane 2, cells grown with 
paromomycin;  lane 3, cells grown with azithromycin; lane 4, cells grown with 5mM VRC;  lane 
5, cells grown with paromomycin and 5mM VRC;  lane 6, cells grown with azithromycin and 
5mM VRC. (b) Agilent chip analysis of RNA from MRSA cells.  Sample lanes are the same as 
in (a). 
 
 
 
 
(a) MSSA (b) MRSA 
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Table 4.3.  Distribution of small RNA species after Agilent gel separation 
 
Strain Inhibitor % Total area
a
 
Methicillin sensitive S. aureus (MSSA) none 15.60±0.6 
MSSA paromomycin       28.90±0.005 (185.3) * 
MSSA azithromycin           41.10±3.2 (263.5) * 
MSSA VRC        19.20±1.0 (123.1) 
MSSA paromomycin + VRC           19.70±0.2 (126.3) * 
MSSA azithromycin + VRC           26.70±0.8 (171.2) * 
Methicillin resistant S. aureus (MRSA) None   8.80±0.4 
MRSA paromomycin       14.35±0.5 (163.1) 
MRSA azithromycin          25.05±2.0 (284.7) * 
MRSA VRC          14.80±0.4 (168.2) * 
MRSA paromomycin + VRC       11.80±1.0 (134.1) 
MRSA azithromycin + VRC          31.10±0.1 (353.4) * 
a
 Total RNA in gel bands smaller than 16S rRNA was computed by analysis of the 
electropherograms using Agilent software. Results are the means ± standard error of 2 
independent experiments. (*) statistically significant with a P value <0.05 
 
 
In order to determine if VRC could be used as an antimicrobial agent in eukaryotic cells, 
the compound and antibiotics were applied to fibroblasts and to macrophage cells in culture. 
When antibiotics were added to the eukaryotic cells, there was no significant change in overall 
cellular viability. However, when 1mM or 5mM VRC was added to the eukaryotic cell cultures, 
there was a 90% and 98% reduction in cell viability. This led to the conclusion that VRC could 
not be used to enhance antibiotic effectiveness in eukaryotic cells.  
 
 
Discussion 
The bacterial ribosome is an important target for current antibiotic treatments 
3
. These 
antimicrobial agents target both translation and ribosomal subunit formation 
4
. For ribosomal 
subunit biogenesis, a number of different endo-and exoribonucleases are required. These include 
RNases III, E, G, T and PH 
6
. This processed RNA is used to form the subunit precursors and 
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without an inhibitor present, the precursors mature to generate the 30S and 50S ribosomal 
subunits respectively 
5
. 
 As previously stated, other endo- and exoribonucleases are required to complete the 
processing of 16S, 23S, and 5S rRNA. This processed RNA is used to form the 21S and 32S 
subunit precursors and without an inhibitor present, the precursors mature to form the 30S and 
50S ribosomal subunits respectively 
5
.  When an inhibitor, such as an antibiotic, is present the 
precursor RNA is broken down. Ribonucleases are used by the cell to degrade the subunit 
precursors and their rRNA into nucleotides to be recycled 
4, 5, 19
. RNase activity is therefore an 
important mechanism for both mRNA turnover and rRNA processing. 
  Our previous research has shown that E. coli strains deficient in RNase E, RNase II or 
polynucleotide phosphorylase (PNPase) were hypersensitive to azithromycin 
7
. These mutants 
showed an enhanced accumulation of 23S rRNA, a stimulation of rRNA breakdown and a 
reduced recovery rate of 50S ribosomal synthesis after azithromycin removal. These results 
suggested that the use of an RNase inhibitor in bacterial cells could enhance the efficiency of 
current antibiotics.  These mutant strains are increased in sensitivity to the aminoglycoside 
antibiotics, neomycin and paromomycin, while 16S rRNA turnover is stimulated in some of 
these mutant strains as well (A. F., unpublished). 
 The present results can be interpreted to suggest that the antibiotics alone stall subunit 
formation with precursor particle accumulation 
20, 21
. VRC alone inhibits the activity of critical 
rRNA processing RNases. Either antibiotic with VRC causes the accumulation of a subunit 
precursor and the inhibition of rRNA processing, leading to an enhanced inhibitory effect on 
subunit formation and a further reduction in cell viability. The relatively high concentration of 
VRC used here (5mM) and its inhibitory effects on eukaryotic cells would preclude its use as a 
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human antimicrobial agent. Its effects on ribosome synthesis indicate its use as a model 
compound and suggest that inhibition of bacterial RNases can be a novel target for drug 
development.  
 It is important to note that VRC specifically inhibited subunit formation without an effect on 
translation. This reinforces the established idea that translation and subunit assembly are separate 
and equivalent targets for ribosomal antibiotics 
4, 22-24
. Either process can be a targeted by 
specific antimicrobials. The cellular RNase target for VRC is unknown but RNase III is a likely 
target since the formation of both subunits was affected to the same extent. Inhibition of subunit 
assembly-specific RNases by VRC suggests that these RNases may be a target by other small 
molecule inhibitors or by RNA interference approaches. This research further indicates the 
importance of RNases as a novel target in antibiotic research.  
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CHAPTER 5 
SUMMARY 
 
 Antibiotics play an important role in society and global health. As the use and misuse of 
antibiotics increases, so does the prevalence of bacterial antibiotic resistance (Hawkey and Jones 
2009; Rosen 2011; Tenover 2001). Due to this increasing problem, the development of novel 
antibiotic targets is a constant research endeavor. 
 Many commonly used antibiotics function by targeting the bacterial ribosome. 
Aminoglycosides have been shown to bind to the 30S ribosomal subunit to inhibit the recycling 
of the ribosomal subunit and affect the translational accuracy (Foster and Champney 2008; 
Mehta and Champney 2002; Sutcliffe 2005). Additionally, aminoglycoside research has 
demonstrated that these antibiotics also target the 50S ribosomal subunit (Borovinskaya and 
others 2007; Campuzano and others 1979; Scheunemann and others 2010). Macrolides 
specifically target the 50S ribosomal subunit but not the 30S subunit in the bacterial cell 
(Champney 2008; Champney and Burdine 1998b; Champney and Rodgers 2007; Chittum and 
Champney 1995; Silvers and Champney 2005; Usary and Champney 2001). 
 The bacterial ribosome is composed of a small (30S) and large (50S) subunit. Each of these 
subunits are made up of ribosomal RNA and various proteins. The 30S subunit is composed of 
16S rRNA while the 50S subunit is composed of 23S and 5S rRNA (Champney 2003). In order 
for the proper formation of the subunits to occur, the ribosomal RNA must be processed from a 
primary RNA transcript into mature RNA. RNases are the enzymes involved in this process. 
Ribonucleases such as RNase III, E, G, and PH all play pivotal roles in rRNA processing as seen 
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in Figure 1.7 and Table 1.2 (Davies and others 2010; Gutgsell and Jain 2012; Kaczanowska and 
Rydén-Aulin 2007; Song and others 2011). 
 Along with rRNA processing, RNases also play important roles in rRNA degradation and 
turnover. Figure 1.6 illustrates the importance of RNases in rRNA degradation. When an 
inhibitor (such as an antibiotic) is introduced into a bacterial cell during ribosome formation, 
RNases play key roles in the breakdown of the 30S and 50S subunits. Once degraded, the rRNA 
can then be recycled back into the bacterial ribosome assembly process without the attached 
translational inhibitors (Champney 2006). RNases II, R, E, and PNPase are all involved in the 
degradation of rRNA as shown in Table 1.2 (Arraiano and others 2010; Cheng and Deutscher 
2002; 2003; Vanzo and others 1998). 
 Prior RNase research by Silvers and Champney demonstrated that when E. coli cells were 
deficient for RNase E, RNase II, or PNPase, these cells displayed an increased sensitivity to the 
macrolide antibiotic, azithromycin (Silvers and Champney 2005). Additionally, these cells had 
an accumulation of the 32S precursor for the 50S ribosomal subunit and a reduced recovery rate 
of the 50S subunit once the antibiotics were removed. This particular work illustrated the 
importance of ribonucleases in 23S rRNA turnover and antibiotic sensitivity to azithromycin 
(Silvers and Champney 2005). This work also indicated that RNases might serve as a potential 
antibiotic target. 
 A study was conducted to first determine if the absence of RNases in E. coli cells would 
show an increased sensitivity to aminoglycosides (Chapter 2) as was seen for Silvers and 
Champney to a macrolide (Silvers and Champney 2005). The results showed that E. coli cells 
deficient for RNase III, E, R, G, or PH displayed a significant decrease in cell viability in the 
presence of neomycin or paromomycin. Additionally, RNase PH deficient cells demonstrated a 
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significant reduction in 30S and 50S ribosomal subunits and a significant reduction in 16S and 
23S rRNA. RNase III is an essential enzyme in the cleavage of the primary RNA transcript 
(Deutscher 2009). RNases E and G are found to function in the processing of 16S rRNA (Li and 
others 1999). RNase G, along with RNase PH, is involved in maturation of 23S rRNA (Gutgsell 
and Jain 2012; Song and others 2011). In addition to rRNA maturation, RNase is involved in 
rRNA degradation by forming part of the bacterial degradosome (Deutscher 2009; Vanzo and 
others 1998). 
 The data from Chapter 2 and Silvers and Champney (Silvers and Champney 2005) indicated 
that the loss of certain RNases led to an increased susceptibility to currently used antibiotics. 
This finding is an important point because antibiotic resistance to aminoglycosides and 
macrolides is documented (Anderson 1999; Cars and others 2011; Högberg and others 2010; 
Zinner 2005). Novel antibiotic targets, such as ribonucleases, could hold an important key to the 
development of new drugs and the improvement of current ones. 
 Due to the fact that RNase mutants are not found in nature, the second aim of this study was 
to determine if the use of an RNase inhibitor would act to inhibit RNases important to RNA 
maturation and thereby potentiate the effects of an aminoglycoside and a macrolide (Chapter 3). 
Vanadyl Ribonucleoside Complex (VRC) is a low weight molecular inhibitor of RNases that is 
mainly used during RNA isolations (Berger 1987; Berger and others 1980). While it is unknown 
which specific RNases are inhibited by VRC, it has been proposed that VRC specifically targets 
endoribonucleases (Berger 1987). The work showed that VRC led in a slight decrease in viable 
cell counts and had an additive effect on E. coli when azithromycin was also added. 
Paromomycin and VRC led to an increase in viable cells that, while not completely understood, 
could possibly be attributed to a decrease in mRNA turnover. Additionally, the presence of VRC 
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was shown to decrease ribosomal subunit assembly and increase the fragmentation of 16S and 
23S rRNA, especially when azithromycin was also present. This work showed that an inhibitor 
of RNases could be used in gram negative E. coli cells to potentiate the effects of the macrolide, 
VRC. VRC did not appear to increase the overall effectiveness of the aminoglycoside, 
paromomycin. The exact mechanism for why paromomycin and VRC led to an increase in E. 
coli cell viability is not known. The addition of VRC and azithromycin led to a decrease, and the 
addition of VRC and paromomycin or azithromycin led to a significant decrease in cell viability 
for both MSSA and MRSA cells. It is postulated that the reason for the increase in E. coli cells 
incubated paromomycin and VRC is due to the differences in bacterial cell walls in gram 
negative and gram positive bacteria and the different targets of aminoglycoside verses macrolide 
antibiotics. 
 In addition to use of VRC in E. coli, it was hypothesized that VRC would act similarly in 
different bacteria. Methicillin resistant strains of Staphylococcus aureus began as hospital 
acquired infections but as antibiotic resistance spread, the introduction of community acquired S. 
aureus began to appear (Hawkey and Jones 2009; Zinner 2007). The final aim of this research 
was to determine if VRC would potentiate the effects of an aminoglycoside and a macrolide in a 
gram positive bacterial species (Chapter 4).  
 Methicillin sensitive and methicillin resistant Staphylococcus aureus were incubated with 
VRC and paromomycin (an aminoglycoside) or azithromycin (a macrolide). The study 
demonstrated that VRC alone reduced the viable cell counts in both types of S. aureus. The 
addition of VRC also led to a reduction in the assembly of the 30S and 50S assembly in S. 
aureus cells. The results also showed that when either of the antibiotics was added, the effects of 
the antibiotics were potentiated by the VRC. This study further demonstrated that an inhibitor of 
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bacterial RNases is effective in not only gram negative bacteria, as seen in Chapter 3, but also 
potentially dangerous gram positive bacteria (i.e. methicillin resistant S. aureus). A summary of 
all three aims is seen in Table 5.1. The table shows that E. coli lacking specific RNases 
demonstrated an increased sensitivity to aminoglycosides and that the use of VRC led to an 
increase in the inhibitory effects of an aminoglycoside and a macrolide.  
 Together, this study demonstrates a novel antibiotic drug target in the bacterial 
ribonucleases. It also shows a new use for an RNase inhibitor to potentiate the effects of current 
antibiotics in both a gram negative, an antibiotic sensitive gram positive, and an antibiotic 
resistant gram positive bacterial species. While VRC was shown to have cytotoxic effects on 
eukaryotic cells (Chapter 4), future studies to identify different prokaryotic-selective RNase 
inhibitors could be useful to antibiotic research. It would be interesting to determine if antibiotic 
resistant bacterial strains up-regulate specific RNases to increase the rRNA turnover in addition 
to other methods of resistance. Other future areas of research could involve different RNase 
inhibitors to determine if different combinations will increase or decrease antibiotic 
susceptibility. With bacterial resistance to current antibiotics on the rise, it is essential that we 
research innovative antibiotic targets in order to improve global health and safety. 
 
 
 
 
 
 
 
105 
 
Table 5.1: Final dissertation summary 
 
Strain 
RNase 
Mutation 
Aminoglycoside 
Sensitivity 
Macrolide 
Sensitivity 
Inhibit 30S 
Assembly 
Inhibit 50S 
Assembly 
Increased 16S rRNA 
Fragmentation 
Increased 23S rRNA 
Fragmentation 
SK901 None       
D10-1 I       
SK7622 III +  + +  + 
SK5665 E +  +    
SK4803 II       
N7060 I, II, PNPase       
MG1655 I
-
R
-
 I, R +  + + + + 
GW11 G +    +  
SK6639 PNPase       
SK5729 
I, II, 
PNPase, PH 
+  + + + + 
Escherichia coli + VRC  + + + + + + 
Methicillin Sensitive 
Staphylococcus aureus + VRC 
 + + + +   
Methicillin Resistant 
Staphylococcus aureus + VRC 
 + + + +   
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